var title_f27_42_28320="Seborrheic dermatitis face 2";
var content_f27_42_28320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Facial seborrheic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_42_28320=[""].join("\n");
var outline_f27_42_28320=null;
var title_f27_42_28321="Membranous IF";
var content_f27_42_28321=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F74698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F74698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunofluorescence microscopy showing membranous nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy in membranous nephropathy showing diffuse, granular IgG deposition along the capillary walls.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_42_28321=[""].join("\n");
var outline_f27_42_28321=null;
var title_f27_42_28322="Ultrasound of fifth extensor compartment wrist";
var content_f27_42_28322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Ultrasound of the fifth extensor compartment of the wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This ultrasound shows the fifth extensor compartment, in addition to the other structures pictured. The image was obtained with an ultrasound probe placed at the site of the red mark in the photograph.&nbsp;",
"    <div class=\"footnotes\">",
"     ECRL: extensor carpi radialis longus tendon; ECRB: extensor carpi radialis brevis tendon; EPL: extensor pollicis longus; V:&nbsp;fifth extensor&nbsp;compartment, containing extensor digiti minimi.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Blake Boggess, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_42_28322=[""].join("\n");
var outline_f27_42_28322=null;
var title_f27_42_28323="Hepatitis B immune globulin: Patient drug information";
var content_f27_42_28323=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hepatitis B immune globulin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"     see \"Hepatitis B immune globulin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/39/24181?source=see_link\">",
"     see \"Hepatitis B immune globulin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HepaGam B&reg;;",
"     </li>",
"     <li>",
"      HyperHEP B&trade; S/D;",
"     </li>",
"     <li>",
"      Nabi-HB&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F178934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      HepaGam B&reg;;",
"     </li>",
"     <li>",
"      HyperHEP B&trade; S/D",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691458",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop hepatitis B infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702238",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hepatitis B immune globulin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have IgA deficiency, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695245",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11754 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_42_28323=[""].join("\n");
var outline_f27_42_28323=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178933\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178934\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016384\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016383\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016388\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016389\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016391\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016386\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016387\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016392\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016393\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=related_link\">",
"      Hepatitis B immune globulin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/39/24181?source=related_link\">",
"      Hepatitis B immune globulin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_42_28324="Hypophosphatemia in the alcoholic patient";
var content_f27_42_28324=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypophosphatemia in the alcoholic patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/42/28324/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28324/contributors\">",
"     Zalman S Agus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/42/28324/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28324/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/42/28324/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28324/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/42/28324/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alcoholic patient is prone to severe hypophosphatemia, particularly when admitted to the hospital. However, the fall in the serum phosphate concentration may not become prominent until 12 to 36 hours after admission. This sequence is due to underlying chronic phosphate depletion complicated by acute shifts of phosphate into the intracellular compartment. (See",
"    <a class=\"local\" href=\"#H13459332\">",
"     'Etiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The causes and treatment of hypophosphatemia in the alcoholic patient will be reviewed here. The major causes of hypophosphatemia, the clinical manifestations of hypophosphatemia, most of which are due to intracellular phosphate depletion, and the diagnosis and treatment of hypophosphatemia in the general population are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link\">",
"     \"Causes of hypophosphatemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32659?source=see_link\">",
"     \"Signs and symptoms of hypophosphatemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2167?source=see_link\">",
"     \"Diagnosis and treatment of hypophosphatemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13459332\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypophosphatemia can result from reduced intestinal phosphate absorption",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased phosphate excretion (",
"    <a class=\"graphic graphic_table graphicRef71616 \" href=\"UTD.htm?24/38/25195\">",
"     table 1",
"    </a>",
"    ). Both mechanisms may be operative in patients who abuse alcohol:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased intestinal phosphate absorption can result from poor dietary intake of both phosphate and vitamin D, binding of dietary phosphate by antacids given to treat recurring gastritis (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      ),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reduced net intestinal phosphate absorption, which may be induced by chronic diarrhea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link&amp;anchor=H6#H6\">",
"       \"Causes of hypophosphatemia\", section on 'Decreased intestinal absorption'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased urinary phosphate excretion due to reduced proximal phosphate reabsorption can result from secondary hyperparathyroidism induced by deficiency of vitamin D deficiency, which should be measured in alcoholic patients with hypophosphatemia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a direct effect of alcohol. Alcohol-induced proximal tubular dysfunction leads to reduced phosphate reabsorptive capacity that begins to improve within days of abstinence from alcohol [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28324/abstract/1\">",
"       1",
"      </a>",
"      ]. The physiology of phosphate handling within the nephron is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link&amp;anchor=H10#H10\">",
"       \"Causes of hypophosphatemia\", section on 'Increased urinary excretion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, chronic alcoholism can induce cellular phosphate depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28324/abstract/2\">",
"     2",
"    </a>",
"    ]. This is important clinically since the clinical manifestations of hypophosphatemia are thought to be largely due to cellular phosphate depletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32659?source=see_link&amp;anchor=H16063123#H16063123\">",
"     \"Signs and symptoms of hypophosphatemia\", section on 'Consequences of intracellular phosphate depletion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H324348475\">",
"    <span class=\"h2\">",
"     After hospital admission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although phosphate depletion is common in alcoholic patients admitted to the hospital, the fall in the serum phosphate concentration, occasionally to less than 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.32",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    may not become prominent until 12 to 36 hours after admission due to movement of extracellular phosphate into the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28324/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes of hypophosphatemia\", section on 'Internal redistribution'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two factors may contribute to this shift:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alcoholic patients usually receive intravenous therapy with dextrose-containing solutions. Glucose stimulates insulin release, which promotes phosphate uptake by the cells as phosphorylated glucose intermediates [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28324/abstract/4\">",
"       4",
"      </a>",
"      ]. If dextrose-containing infusions are avoided or discontinued, a shift of extracellular phosphate into cells may still occur due to refeeding-induced insulin release.",
"     </li>",
"     <li>",
"      The development of acute respiratory alkalosis due to alcohol withdrawal or other causes of hyperventilation. The elevation in extracellular pH produces a similar pH change within the cells since carbon dioxide can rapidly diffuse across cell membranes. The ensuing intracellular alkalosis stimulates intracellular phosphofructokinase, leading to an increase in glycolysis and movement of phosphate into cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, serial monitoring of the serum phosphate concentration is warranted when alcoholic patients are admitted to the hospital.",
"   </p>",
"   <p>",
"    Hypophosphatemic alcoholic patients may have a myopathy due both to phosphate depletion and to alcohol, and are at risk for clinically significant rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28324/abstract/5\">",
"     5",
"    </a>",
"    ]. The release of intracellular phosphate from damaged muscle cells may be one reason why two potentially fatal sequelae of hypophosphatemia &mdash; respiratory failure and severe central nervous system dysfunction &mdash; are rarely seen in alcoholic patients. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32659?source=see_link\">",
"     \"Signs and symptoms of hypophosphatemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link&amp;anchor=H25326295#H25326295\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\", section on 'Fluid and electrolyte abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to phosphate repletion takes into account the serum phosphate concentration, the presence or absence of overt symptoms of hypophosphatemia, and whether the patient can take oral therapy. If possible, we prefer oral rather than intravenous phosphate therapy, since intravenous repletion can lead to hyperphosphatemia that may result in serious complications such as hypocalcemia, acute kidney injury, and arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2167?source=see_link&amp;anchor=H3136551#H3136551\">",
"     \"Diagnosis and treatment of hypophosphatemia\", section on 'Intravenous dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In",
"      <strong>",
"       asymptomatic",
"      </strong>",
"      patients with a serum phosphate less than 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.64",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we give oral phosphate therapy since many of these patients have myopathy and weakness that are not clinically apparent.",
"     </li>",
"     <li>",
"      The treatment of",
"      <strong>",
"       symptomatic",
"      </strong>",
"      patients varies with the severity of the hypophosphatemia:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We treat with oral phosphate if the serum phosphate is 1.0 to 1.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.32 to 0.63",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      We treat with intravenous phosphate if the serum phosphate is less than 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.32",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and switch to oral replacement when the serum phosphate exceeds 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.48",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We stop phosphate repletion when the serum phosphate is greater than or equal to 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.64",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      unless there is an indication for chronic therapy such as persistent urinary phosphate wasting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Phosphate repletion can be achieved with sodium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/62/27622?source=see_link\">",
"     potassium phosphate",
"    </a>",
"    . Oral repletion is most often achieved with a combined preparation of sodium and potassium phosphate, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    is preferred for intravenous therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H613090\">",
"    <span class=\"h2\">",
"     Oral phosphate therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no available data on oral phosphate repletion in alcoholic patients, we use a dose of 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (0.48 to 0.64",
"    <span class=\"nowrap\">",
"     mmol/kg)",
"    </span>",
"    per day. This dose is lower than that given to patients with hypophosphatemia due to renal phosphate wasting in whom raising the serum phosphate will increase phosphate excretion, thereby limiting the increase in serum phosphate. If present, a defect in proximal tubular phosphate reabsorption is usually mild in alcoholic patients and begins to reverse soon after admission to the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28324/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2167?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis and treatment of hypophosphatemia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H613139\">",
"    <span class=\"h2\">",
"     Intravenous phosphate therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two main indications for intravenous phosphate therapy in alcoholic patients: an inability to take or tolerate oral phosphate supplementation or a serum phosphate concentration below 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.32",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in patients who have overt symptoms of hypophosphatemia.",
"   </p>",
"   <p>",
"    The dose of intravenous phosphate is the same in alcoholic and non-alcoholic patients. Because of the potential adverse effects of inducing hyperphosphatemia, the serum phosphate concentration should be measured every six hours. Intravenous phosphate supplementation should be discontinued when the serum phosphate is above 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.48",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Intravenous phosphate repletion is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2167?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis and treatment of hypophosphatemia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H613179\">",
"    <span class=\"h2\">",
"     Avoidance of dextrose-containing fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, hypophosphatemia in alcoholic patients often occurs or is exacerbated after admission to the hospital due to phosphate movement from the extracellular fluid into the cells. This may be driven in part by the release of insulin following the administration of dextrose-containing intravenous fluids. Thus, dextrose-containing fluids should",
"    <strong>",
"     not",
"    </strong>",
"    be given in patients who are hypophosphatemic at presentation and do not have an indication for dextrose therapy (eg, hypoglycemia, alcoholic ketoacidosis). (See",
"    <a class=\"local\" href=\"#H324348475\">",
"     'After hospital admission'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6613?source=see_link&amp;anchor=H5#H5\">",
"     \"Alcoholic and fasting ketoacidosis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22311795\">",
"    <span class=\"h2\">",
"     Vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency may contribute to hypophosphatemia in alcoholic patients, and should be corrected if present. (See",
"    <a class=\"local\" href=\"#H13459332\">",
"     'Etiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13459013\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The alcoholic patient often has chronic phosphate depletion, and, after admission to the hospital, is prone to severe hypophosphatemia resulting from redistribution of extracellular phosphate into the cells. This intracellular shift can be mediated by one or both of two mechanisms: the release of insulin induced by the administration of dextrose-containing fluid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      refeeding; and acute respiratory alkalosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H324348475\">",
"       'After hospital admission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major causes of chronic phosphate depletion in the alcoholic patient include poor dietary intake of both phosphate and vitamin D, binding of dietary phosphate by antacids used to treat recurring gastritis, chronic diarrhea, and increased urinary phosphate excretion which can result from secondary hyperparathyroidism induced by vitamin D deficiency",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a proximal tubular defect associated with alcohol abuse. (See",
"      <a class=\"local\" href=\"#H13459332\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After admission to the hospital, the acute shift of phosphate into cells is primarily caused by increased insulin release due to intravenous solutions containing dextrose, and may also result from acute respiratory alkalosis. (See",
"      <a class=\"local\" href=\"#H324348475\">",
"       'After hospital admission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In alcoholic patients with hypophosphatemia and a serum phosphate less than 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.64",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we suggest phosphate repletion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Even if these patients are not overtly symptomatic, they may have myopathy and weakness that are clinically apparent. We suggest the following approach: (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In",
"      <strong>",
"       asymptomatic",
"      </strong>",
"      patients with a serum phosphate less than 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.64",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we give oral phosphate therapy.",
"     </li>",
"     <li>",
"      The treatment of",
"      <strong>",
"       symptomatic",
"      </strong>",
"      patients varies with the severity of the hypophosphatemia: oral phosphate if the serum phosphate is 1.0 to 1.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.32 to 0.63",
"      <span class=\"nowrap\">",
"       mmol/L);",
"      </span>",
"      and intravenous phosphate if the serum phosphate is less than 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.32",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      with a switch to oral replacement when the serum phosphate exceeds 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.48",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      We stop phosphate repletion when the serum phosphate is greater than or equal to 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.64",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      unless there is an indication for chronic therapy such as persistent urinary phosphate wasting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When using oral therapy in alcoholic patients with hypophosphatemia, we usually treat with 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.48 to 0.64",
"      <span class=\"nowrap\">",
"       mmol/kg)",
"      </span>",
"      per day. (See",
"      <a class=\"local\" href=\"#H613090\">",
"       'Oral phosphate therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dose of intravenous phosphate is the same in alcoholic and non-alcoholic patients. Because of the potential adverse effects of inducing hyperphosphatemia, the serum phosphate concentration should be measured every six hours. (See",
"      <a class=\"local\" href=\"#H613139\">",
"       'Intravenous phosphate therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2167?source=see_link&amp;anchor=H3136551#H3136551\">",
"       \"Diagnosis and treatment of hypophosphatemia\", section on 'Intravenous dosing'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Dextrose-containing intravenous fluids should be avoided in alcoholic patients who are hypophosphatemic at presentation and do not have an indication for dextrose therapy (eg, hypoglycemia, alcoholic ketoacidosis). (See",
"      <a class=\"local\" href=\"#H613179\">",
"       'Avoidance of dextrose-containing fluids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28324/abstract/1\">",
"      De Marchi S, Cecchin E, Basile A, et al. Renal tubular dysfunction in chronic alcohol abuse--effects of abstinence. N Engl J Med 1993; 329:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28324/abstract/2\">",
"      Ferguson ER, Blachley JD, Carter NW, Knochel JP. Derangements of muscle composition, ion transport, and oxygen consumption in chronically alcoholic dogs. Am J Physiol 1984; 246:F700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28324/abstract/3\">",
"      Knochel JP. Hypophosphatemia in the alcoholic. Arch Intern Med 1980; 140:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28324/abstract/4\">",
"      Marinella MA. Refeeding syndrome and hypophosphatemia. J Intensive Care Med 2005; 20:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28324/abstract/5\">",
"      Knochel JP. The pathophysiology and clinical characteristics of severe hypophosphatemia. Arch Intern Med 1977; 137:203.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 843 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_42_28324=[""].join("\n");
var outline_f27_42_28324=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13459013\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13459332\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H324348475\">",
"      After hospital admission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H613090\">",
"      Oral phosphate therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H613139\">",
"      Intravenous phosphate therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H613179\">",
"      Avoidance of dextrose-containing fluids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22311795\">",
"      Vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13459013\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/843\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/843|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/38/25195\" title=\"table 1\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6613?source=related_link\">",
"      Alcoholic and fasting ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=related_link\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2167?source=related_link\">",
"      Diagnosis and treatment of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32659?source=related_link\">",
"      Signs and symptoms of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_42_28325="Eribulin: Drug information";
var content_f27_42_28325=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Eribulin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/14/29923?source=see_link\">",
"    see \"Eribulin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11247325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Halaven&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15572584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Halaven&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F11236545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimicrotubular",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11261455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Breast cancer, metastatic:",
"     </b>",
"     I.V.: 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on days 1 and 8 of a 21-day treatment cycle",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F11261459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11261451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Reduce to 1.1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F11261452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild hepatic impairment (Child-Pugh class A): Reduce to 1.1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate hepatic impairment (Child-Pugh class B): Reduce to 0.7 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe hepatic impairment (Child-Pugh class C): Use has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F11261453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &lt;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or grade 3 or 4 nonhematologic toxicity on day 1 or 8: Withhold dose; may delay day 8 dose up to 1 week. If toxicity resolves to &le;grade 2 by day 15 administer a reduced dose and wait at least 2 weeks before beginning the next cycle. Omit dose if not resolved to &le;grade 2 by day 15. Do not re-escalate dose after reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Permanently reduce dose from 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 1.1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &gt;7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     with fever or infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     requiring transfusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nonhematologic toxicity of grade 3 or 4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dose omission or delay due to toxicity on day 8 of prior cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Permanently reduce dose from 1.1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 0.7 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for occurrence of any of the above events; discontinue treatment if the above toxicities occur at the 0.7 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     dose level.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11247326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as mesylate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Halaven&trade;: 0.5 mg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F11258609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11261457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Infuse over 2-5 minutes. May be administered undiluted or diluted.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:0em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F11261432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in normal saline;",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dextrose",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11236547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic breast cancer in patients who have received at least 2 prior chemotherapy regimens",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11258608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       EriBULin may be confused with EPIrubicin, erlotinib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11261424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (54%), fever (21%), headache (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Alopecia (45%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (35%), stomatitis (5% to 18%), constipation (25%), weight loss (21%), anorexia (20%), diarrhea (18%), vomiting (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenia (82%; grades 3: 28%; grade 4: 29%; nadir: 13 days; recovery: 8 days), anemia (58%; grades 3/4: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (54%), peripheral neuropathy (35%; grades 3/4: &le;8%), arthralgia/myalgia (22%), back pain (16%), bone pain (12%), limb pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (16%), cough (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Depression, dizziness, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Mucosal inflammation (9%), abdominal pain, dyspepsia, taste alteration, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenic fever (5%), thrombocytopenia (grades 3/4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Muscle spasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Lacrimation increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Pharyngolaryngeal pain, sepsis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11258613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling (not in U.S. labeling): Hypersensitivity to eribulin mesylate, halichondrin B, or its chemical derivatives.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11258614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bone marrow suppression: Hematologic toxicity, including severe neutropenia,  has occurred. May require treatment delay and dosage reduction. A higher incidence of grade 4 neutropenia and neutropenic fever occurred in patients with ALT or AST &gt;3 x ULN or bilirubin &gt;1.5 x ULN. Monitor complete blood counts prior to each dose; more frequently if severe cytopenias develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Peripheral neuropathy: Peripheral neuropathy is a common toxicity; may be prolonged (&gt;1 year in 5% of patients).  May require treatment delay. Monitor for signs of motor or sensory neuropathy. Some patients may have pre-existing neuropathy due to prior chemotherapy; monitor closely for worsening.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; QT prolongation: QT prolongation was observed on day 8 (in an uncontrolled study). Monitor ECG in patients with heart failure, bradyarrhythmia, and with concomitant medication known to prolong the QT interval. Correct hypokalemia and hypomagnesemia prior  to treatment; monitor electrolytes periodically during treatment. Avoid use in patients with congenital long QT syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Dosage reduction required in patients with mild-to-moderate (Child-Pugh class A or B) hepatic impairment; use has not been studied in patients with severe hepatic impairment. Transaminase or bilirubin elevations are associated with a higher incidence of grade 4 neutropenia and neutropenic fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Dosage reduction required in patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute); use has not been studied in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11304578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiarrhythmic Agents (Class Ia): EriBULin may enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiarrhythmic Agents (Class III): EriBULin may enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11258610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11258611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenicity and fetal loss were observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action, eribulin would be expected to cause fetal harm if administered during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11258612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11261664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Halaven Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/2 mL (2 mL): $1114.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11261461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential prior to each dose; renal and liver function tests; serum electrolytes, including potassium and magnesium. Assess for peripheral neuropathy prior to each dose. Monitor ECG in patients with heart failure, bradyarrhythmia, and with concomitant medication known to prolong the QT interval, and electrolyte abnormalities (eg, hypokalemia, hypomagnesemia).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Halaven (CH, CZ, DE, DK, EE, FR, GB, JP, NO, SE, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11261433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Eribulin is a non-taxane microtubule inhibitor which is a halichondrin B analog. It inhibits the growth phase of the microtubule by inhibiting formation of mitotic spindles causing mitotic blockage and arresting the cell cycle at the G",
"     <sub>",
"      2",
"     </sub>",
"     /M phase; suppresses microtubule polymerization yet does not affect depolymerization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11261435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 43-114 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 49% to 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: ~40 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (82%; predominantly as unchanged drug); urine (9%, primarily as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cortes J, Vahdat L, Blum JL, et al, &ldquo;Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(25):3922-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/42/28325/abstract-text/20679609/pubmed\" id=\"20679609\" target=\"_blank\">",
"        20679609",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jansen M, Vernaz-Gris M, DesJardins C, et al, &ldquo;Population Pharmacokinetics (PPK) of Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer (MBC),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(15s):2524 [abstract 2524 from 2009 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Twelves C, Loesch, D, Blum JL, et al, &ldquo;A Phase III Study (EMBRACE) of Eribulin Mesylate Versus Treatment of Physician&rsquo;s Choice in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated  With an Anthracycline and a Taxane,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28 (18s):CRA1004 [abstract CRA1004 from 2010 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Twelves C, Vahdat LT, Akerele CE, et al, &ldquo;Eribulin Mesylate (E7389) Versus Treatment of Physician&rsquo;s Choice in Patients (pts) With Metastatic Breast Cancer (MBC): A Phase III Study (EMBRACE),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010:257 [abstract 257 from 2010 ASCO Breast Cancer Symposium].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vahdat LT, Pruitt B, Fabian CJ, et al, &ldquo;Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(18):2954-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/42/28325/abstract-text/19349550/pubmed\" id=\"19349550\" target=\"_blank\">",
"        19349550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Witteveen P, Marchette S, Mergui-Roelvink M, et al, &ldquo;Eribulin Mesylate Pharmacokinetics in Patients With Hepatic Impairment,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(15s):2582 [abstract 2582 from 2010 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16096 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.102.30.19-4C5AE98573-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_42_28325=[""].join("\n");
var outline_f27_42_28325=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11247325\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15572584\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11236545\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11261455\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11261459\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11261451\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11261452\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11261453\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11247326\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11258609\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11261457\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11261432\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11236547\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11258608\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11261424\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11258613\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11258614\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299279\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11304578\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11258610\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11258611\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11258612\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11261664\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322878\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11261461\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992820\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11261433\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11261435\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16096\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16096|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/14/29923?source=related_link\">",
"      Eribulin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_42_28326="Achilles tendon anatomy";
var content_f27_42_28326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Anatomy of the Achilles tendon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 597px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_42_28326=[""].join("\n");
var outline_f27_42_28326=null;
var title_f27_42_28327="Nitrosourea-induced pulmonary injury";
var content_f27_42_28327=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"25\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nitrosourea-induced pulmonary injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/42/28327/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28327/contributors\">",
"     Ronan O'Driscoll, BSc, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/42/28327/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28327/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28327/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/42/28327/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28327/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28327/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/42/28327/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nitrosourea drugs, a class of DNA alkylating agents related to nitrogen mustards, include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    (BCNU),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    (CCNU), semustine (methyl CCNU), and chloroethylnitrosourea (Sar-CNU). Nitrosourea drugs are used to treat lymphoma, brain tumors, melanoma, and other solid tumors including breast cancer. Carmustine is the most widely used nitrosourea, and is associated with acute and chronic pulmonary toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Pulmonary fibrosis has also followed treatment with semustine and chloroethylnitrosourea [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients develop pulmonary fibrosis within three years of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    treatment; however, some patients develop breathlessness and aggressive fibrosis decades after exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The reported incidence of carmustine-induced pulmonary toxicity has ranged from 20 to 30 percent in some studies, to as low as 1 percent in others [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/1\">",
"     1",
"    </a>",
"    ]. The low incidence of pulmonary fibrosis in some series may be due to a short observation period, low dose carmustine therapy, or the short median survival of patients with aggressive tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     Carmustine",
"    </a>",
"    is also used in the management of patients with lymphoma who require high dose chemotherapy in conjunction with hematopoietic stem cell support [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients who received carmustine as part of their preparative regimen for hematopoietic stem cell transplantation have a longer window for the development of pulmonary complications. In this setting the incidence of interstitial pneumonitis or idiopathic pneumonia has been reported to be 2 to 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors have suggested that this syndrome should be considered \"idiopathic pneumonia syndrome\" in the context of hematopoietic stem cell transplantation, because the etiology and histology of the lung abnormality are poorly characterized in many cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, these patients are exposed to a single dose or short course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    in combination with other chemotherapy agents, whereas use of carmustine for other disorders requires repeated cycles of chemotherapy over a period of up to two years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link&amp;anchor=H17#H17\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\", section on 'Idiopathic pneumonia syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EARLY ONSET LUNG FIBROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 25 percent of patients in whom",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    is administered will develop pulmonary fibrosis during the ensuing 36 months, if they survive their malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/1-3,7,9,10,13,14\">",
"     1-3,7,9,10,13,14",
"    </a>",
"    ]. Lung fibrosis is especially likely with very high doses (above 1500 mg per square meter), the concurrent administration of other agents with pulmonary toxicity (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ), and possibly by preexisting lung disease, localized chest wall radiotherapy, or atopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    dose has been examined in multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. One study of 94 patients with Hodgkin lymphoma who had received high dose chemotherapy including carmustine found that the incidence of interstitial pneumonitis increased with increasing doses of carmustine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      15 percent incidence with doses less than 475 mg per square meter",
"     </li>",
"     <li>",
"      32 percent with doses between 475 and 525 mg per square meter",
"     </li>",
"     <li>",
"      47 percent with doses greater than 525 mg per square meter (26 percent fatal)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multivariate analysis found that the total amount of administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    and female gender were the only independent variables associated with the development of lung disease.",
"   </p>",
"   <p>",
"    Children also develop pulmonary toxicity from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    . In a study of 73 children with glioma, seven developed interstitial pneumonitis 3 to 11 months after adjuvant chemotherapy with carmustine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and cisplatinum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/18\">",
"     18",
"    </a>",
"    ]. The median cumulative dose of carmustine was 460 mg per m",
"    <sup>",
"     2",
"    </sup>",
"    . Six of the seven patients died of progressive lung disease.",
"   </p>",
"   <p>",
"    It is not yet known if exposure to a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    carries a greater or lesser risk of lung toxicity than exposure to the same total dose given in smaller aliquots over a period of one to two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with early-onset",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    -induced lung fibrosis usually present within weeks to months of treatment with dry cough, breathlessness, and bilateral inspiratory crackles. Others may present within days to weeks of carmustine treatment with a fulminant illness similar to acute respiratory distress syndrome (ARDS). Many other patients may have subclinical disease detected by pulmonary function testing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/2,14,17,19,20\">",
"     2,14,17,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph and computed tomographic (CT) scan appearances are variable. Radiographic imaging may show bilateral diffuse opacities or nodules, localized consolidation, or localized or diffuse interstitial fibrotic changes. In fulminant cases, the radiographic picture may suggest pulmonary edema or ARDS. Apical pleural thickening, spontaneous pneumothoraces (both usually many months after treatment), and fibrotic \"stranding\" have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with early onset pulmonary fibrosis have decreased vital capacity and total lung capacity. In addition, a reduced diffusing capacity for carbon monoxide (DLCO) is one of the most sensitive markers of early",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    lung toxicity, and may occur when patients are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/2,14,17,19,20,22\">",
"     2,14,17,19,20,22",
"    </a>",
"    ]. Measurements of DLCO can be a very useful early marker of pulmonary toxicity, since diffusion abnormalities frequently precede the radiologic changes in affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/2\">",
"     2",
"    </a>",
"    ]. Administration of corticosteroids may reverse this fall in DLCO and any associated symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/14,19,20\">",
"     14,19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine blood tests are unhelpful in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    lung injury, and the authors are unaware of any reports of bronchoalveolar lavage in the early onset syndrome. Arterial blood gas analysis reveals hypoxemia in advanced cases (with normal or low PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lung pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy and autopsy reports have primarily described florid interstitial fibrosis with varying degrees of edema and hyaline membrane formation. Electron microscopic studies have revealed disappearance of type I pneumocytes, marked hyperplasia and hypertrophy of type II pneumocytes, and interstitial deposits of collagen. Increased expression of fibrogenic factors, including platelet-derived growth factor-B and transforming growth factor beta-1, has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have been minimally effective in some reports [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] but have been helpful in other cases, especially if given early to patients identified to be at risk based upon early symptoms or a fall in DLCO [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/8,14,19,20\">",
"     8,14,19,20",
"    </a>",
"    ]. As an example, one study reported complete response in 15 of 17 cases given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    at a dose of 1 mg per kg for 10 days, then tapered to 5 mg every other day [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/8\">",
"     8",
"    </a>",
"    ]. Although many patients with an acute presentation have recovered, many patients with severe disease have died within days to months. Patients with milder disease usually survive, especially if they have received low doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    or if they respond well to steroid therapy, but it is possible that these individuals may be at increased risk of late pulmonary fibrosis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     Carmustine",
"    </a>",
"    should be withdrawn if lung fibrosis is suspected. Prior to each carmustine treatment, it is",
"    <strong>",
"     strongly recommended",
"    </strong>",
"    that diffusing capacity (DLCO) be measured. Carmustine should be withdrawn if there is a measurable fall (ie, &gt;10 percent) in DLCO, and it would seem prudent to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    in a dose of 20 to 40 mg per day or prednisolone in a dose of 1 mg per",
"    <span class=\"nowrap\">",
"     kg/day",
"    </span>",
"    until this fall (and any associated symptoms) are abolished [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/8,14,19,20\">",
"     8,14,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;These general measures may reduce the incidence and severity of early-onset pulmonary fibrosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lowest possible dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      should be used because there is good evidence that higher doses are more likely to cause pulmonary toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/15-17\">",
"       15-17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients should undergo serial monitoring of DLCO and KCO. Steroids should be given if these values decrease by more than 10 percent, as described above [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/8,14,19,20\">",
"       8,14,19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High dose inhaled steroids may reduce the risk of pulmonary toxicity, based on the findings of a single study. In this trial, 63 patients who received inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      were compared with 45 historical controls treated at the same center with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      -containing chemotherapy and autologous hematopoietic stem cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/23\">",
"       23",
"      </a>",
"      ]. Pulmonary toxicity occurred in 35 percent of patients treated with inhaled steroid compared with 73 percent of historical controls.",
"     </li>",
"     <li>",
"      The only way to totally avoid the risk of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      -induced pulmonary toxicity is to avoid the use of carmustine. One alternative regime, tested in 191 patients with breast cancer, included",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"       thiotepa",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      followed by autologous hematopoietic stem cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/24\">",
"       24",
"      </a>",
"      ]. Response and five-year survival rates for this group were similar to historical controls. There were two deaths due to diffuse alveolar hemorrhage, but no episodes of delayed interstitial pneumonitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LATE ONSET LUNG FIBROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late onset lung fibrosis as a complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    therapy was initially described in a Manchester, United Kingdom study of 17 survivors of childhood brain tumors who had been treated with carmustine (",
"    <a class=\"graphic graphic_picture graphicRef71882 \" href=\"UTD.htm?27/13/27860\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/4,25,26\">",
"     4,25,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two patients (12 percent) died of lung fibrosis within three years of treatment.",
"     </li>",
"     <li>",
"      After 16 to 25 years of follow-up, a total of nine patients had died of lung fibrosis.",
"     </li>",
"     <li>",
"      All eight long-term survivors who were studied had evidence of lung fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/4,25-28\">",
"       4,25-28",
"      </a>",
"      ]. The lung function of these patients slowly deteriorated over many years, a result which suggests that all patients who have received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      may be at risk of late-presenting lung fibrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following clinical characteristics of late onset fibrosis are drawn from observations in this cohort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients had no symptoms for several years, although the chest radiographs and lung function studies showed evidence of lung fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/4\">",
"     4",
"    </a>",
"    ]. The patients with the most severe fibrotic changes developed breathlessness (and sometimes cough) at a late stage of the disease. Although the mean interval from treatment to first symptoms was nine years, the interval from first symptoms to death was only one year. All patients had restricted lung function but only one had crackles on chest auscultation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two patients had normal chest radiographs and high resolution CT scans (HRCT) despite physiologic and biopsy evidence of lung fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/4,27\">",
"     4,27",
"    </a>",
"    ]. The other six patients had radiographic and HRCT changes of varying severity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main features were upper zone patchy and linear opacities and volume loss (elevated pulmonary hila) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51903 \" href=\"UTD.htm?16/41/17044\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Apical pleural thickening was noted in two of the fatal cases",
"     </li>",
"     <li>",
"      HRCT scans showed coarse linear strands lying mainly in the upper lobes with some confluent sub-pleural bands which suggested pleural thickening (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61118 \" href=\"UTD.htm?19/57/20368\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gallium lung scans were negative in all cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with late-presenting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    lung fibrosis have restricted lung volumes (FVC and total lung capacity 50 to 60 percent of predicted values). However, unlike early onset carmustine fibrosis, the diffusing capacity is normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;No overall excess of polymorphonuclear cells or lymphocytes (or lymphocyte subsets) was observed on bronchoalveolar lavage. However, mononuclear cells yielded a lower than normal population of mature macrophages and a higher than normal population of immature monocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/4\">",
"     4",
"    </a>",
"    ]. High numbers of cells expressed cell markers which are associated with fibrosis, and a high proportion of the macrophages contained fibronectin, which is also associated with fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Lung pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Light microscopy revealed interstitial pulmonary fibrosis and elastosis but no inflammatory infiltrate. Findings on electron microscopy included focal but marked interstitial fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/4,28\">",
"     4,28",
"    </a>",
"    ]. In addition, the type I (membranous) pneumocytes exhibited electron lucency and had been shed in some areas, leaving a bare basement membrane. Type II cells had an increased number of lamellar bodies, and some contained multiple large vacuoles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Dose-response relationship",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the severity of lung fibrosis in the Manchester cohort was not related to the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    , higher doses of carmustine were given in the 1970s than are used now. All of the patients had received at least 700 mg per m",
"    <sup>",
"     2",
"    </sup>",
"    of carmustine, and 12 of 17 had received &gt;1000 mg per m",
"    <sup>",
"     2",
"    </sup>",
"    , including 7 of 9 who died of pulmonary fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of late-onset lung fibrosis is unknown. The DNA of alveolar cells may be damaged by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    , with subsequent toxicity to the delicate control systems within the alveolus. Despite the long time course, some of the pathologic changes are similar to those observed in acute respiratory distress syndrome (ARDS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;No treatment has been shown to influence the course of late",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    lung injury. The absence of inflammation on biopsies suggests that glucocorticoids are unlikely to be beneficial. In patients observed for up to 25 years, a gradual fall in vital capacity and total lung capacity has been seen (",
"    <a class=\"graphic graphic_figure graphicRef51387 \" href=\"UTD.htm?11/0/11278\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Lung transplantation offers the best hope of long-term survival for severely affected patients. The prognosis seems to be much worse for those treated below the age of seven years. By comparison, patients who were treated beyond the age of puberty had the best lung function and the slowest rate of decline [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Implications for other fibrosis-inducing agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similar syndrome of late-onset pulmonary fibrosis has been described after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=see_link\">",
"     \"Cyclophosphamide pulmonary toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37415?source=see_link\">",
"     \"Busulfan-induced pulmonary injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41380?source=see_link\">",
"     \"Chlorambucil-induced pulmonary injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The magnitude of the risk of delayed pulmonary fibrosis after treatment for cancer was illustrated by a questionnaire survey of over 12,000 survivors of childhood and adolescent cancer and 3500 of their siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/29\">",
"     29",
"    </a>",
"    ]. The cumulative incidence of pulmonary fibrosis among survivors who had received chest radiation was 3.5 percent at 20 years after diagnosis. The relative risk in those who had received chest radiation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy was significantly increased compared to their untreated siblings (4.3, 1.6, 1.4, 2.1, 0.6, and 1.3, respectively). These patients were not screened for lung fibrosis and the true risk may be much higher because patients can remain asymptomatic for many years and most patients with severe fibrosis would not be available for screening because of the high mortality from this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28327/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional late-presenting lung problems will probably be observed because of the increasing numbers of long-term survivors of malignancy. Other alkylating agents are likely to pose the greatest theoretical risk. However, any agent which damages the DNA of lung cells could theoretically cause delayed lung damage, just as radiation-induced lung damage can progress over a long time period. As a result, pulmonary physicians should be alert when confronted with apparently unexplained lung and pleural disease in patients with previous cancer treatment, even if such treatment occurred more than 20 years prior to the development of pulmonary symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116138845\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nitrosourea drugs, of which",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      (BCNU) is the most commonly used, are associated with early onset (within three years of treatment) and late onset (after three years) pulmonary toxicity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for early onset pulmonary toxicity include higher doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      (especially doses above 1500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and the concurrent administration of other agents that cause pulmonary toxicity (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ). Other factors that may contribute include underlying lung disease, localized chest wall radiotherapy, and atopy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Early onset lung fibrosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early onset pulmonary toxicity presents with a nonproductive cough, dyspnea, and crackles on examination. Imaging studies show bilateral, reticular or ground glass opacities. The diagnosis is usually established based upon the history of drug exposure and a compatible clinical picture, but is a diagnosis of exclusion. The differential diagnosis includes radiation-induced lung injury, pulmonary edema, infection, lung involvement by an underlying malignancy, and pulmonary thromboembolism. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Early onset lung fibrosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of early onset lung toxicity is largely supportive. The role of systemic glucocorticoids is unclear, although they are often administered to patients who develop symptomatic interstitial lung disease in the setting of nitrosourea therapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      &nbsp;is also a risk factor for late-onset pulmonary fibrosis, which is fatal in approximately 50 percent and typically presents with radiographic upper lung zone patchy and linear opacities with volume loss and physiologic evidence of pulmonary restriction in long-term survivors. The absence of inflammation on lung biopsy suggests that glucocorticoids are unlikely to be beneficial. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Late onset lung fibrosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/1\">",
"      Weiss RB, Poster DS, Penta JS. The nitrosoureas and pulmonary toxicity. Cancer Treat Rev 1981; 8:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/2\">",
"      Selker RG, Jacobs SA, Moore PB, et al. 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis. Neurosurgery 1980; 7:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/3\">",
"      Durant JR, Norgard MJ, Murad TM, et al. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). Ann Intern Med 1979; 90:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/4\">",
"      O'Driscoll BR, Hasleton PS, Taylor PM, et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990; 323:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/5\">",
"      Wong RP, Baetz T, Krahn MJ, et al. SarCNU in recurrent or metastatic colorectal cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 2006; 24:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/6\">",
"      Webster M, Cairncross G, Gertler S, et al. Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a phase II trial of the national cancer institute of canada clinical trials group. Invest New Drugs 2005; 23:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/7\">",
"      Weinstein AS, Diener-West M, Nelson DF, Pakuris E. Pulmonary toxicity of carmustine in patients treated for malignant glioma. Cancer Treat Rep 1986; 70:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/8\">",
"      Alessandrino EP, Bernasconi P, Colombo A, et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000; 25:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/9\">",
"      Wadhwa PD, Fu P, Koc ON, et al. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality. Biol Blood Marrow Transplant 2005; 11:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/10\">",
"      Wong R, Rondon G, Saliba RM, et al. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. Bone Marrow Transplant 2003; 31:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/11\">",
"      Frankovich J, Donaldson SS, Lee Y, et al. High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes. Biol Blood Marrow Transplant 2001; 7:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/12\">",
"      Clark JG, Hansen JA, Hertz MI, et al. NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993; 147:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/13\">",
"      Shen YC, Chiu CF, Chow KC, et al. Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2. Bone Marrow Transplant 2004; 34:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/14\">",
"      Cao TM, Negrin RS, Stockerl-Goldstein KE, et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000; 6:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/15\">",
"      Schmitz N, Diehl V. Carmustine and the lungs . Lancet 1997; 349:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/16\">",
"      Rubio C, Hill ME, Milan S, et al. Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease. Br J Cancer 1997; 75:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/17\">",
"      Ager S, Mahendra P, Richards EM, et al. High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study. Bone Marrow Transplant 1996; 17:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/18\">",
"      Chastagner P, Kalifa C, Doz F, et al. Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study. Pediatr Blood Cancer 2007; 49:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/19\">",
"      Chap L, Shpiner R, Levine M, et al. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment. Bone Marrow Transplant 1997; 20:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/20\">",
"      Kalaycioglu M, Kavuru M, Tuason L, Bolwell B. Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU). Chest 1995; 107:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/21\">",
"      Parish JM, Muhm JR, Leslie KO. Upper lobe pulmonary fibrosis associated with high-dose chemotherapy containing BCNU for bone marrow transplantation. Mayo Clin Proc 2003; 78:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/22\">",
"      Lind PA, Marks LB, Jamieson TA, et al. Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue. Cancer 2002; 94:2821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/23\">",
"      McGaughey DS, Nikcevich DA, Long GD, et al. Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant 2001; 7:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/24\">",
"      Damon LE, Wolf JL, Rugo HS, et al. High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant 2000; 26:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/25\">",
"      O'Driscoll BR, Kalra S, Gattamaneni HR, Woodcock AA. Late carmustine lung fibrosis. Age at treatment may influence severity and survival. Chest 1995; 107:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/26\">",
"      Lohani S, O'Driscoll BR, Woodcock AA. 25-year study of lung fibrosis following carmustine therapy for brain tumor in childhood. Chest 2004; 126:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/27\">",
"      Taylor PM, O'Driscoll BR, Gattamaneni HR, Woodcock AA. Chronic lung fibrosis following carmustine (BCNU) chemotherapy: radiological features. Clin Radiol 1991; 44:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/28\">",
"      Hasleton PS, O'Driscoll BR, Lynch P, et al. Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma. J Pathol 1991; 164:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28327/abstract/29\">",
"      Mertens AC, Yasui Y, Liu Y, et al. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer 2002; 95:2431.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4354 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_42_28327=[""].join("\n");
var outline_f27_42_28327=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H116138845\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EARLY ONSET LUNG FIBROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lung pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LATE ONSET LUNG FIBROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Lung pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Dose-response relationship",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Implications for other fibrosis-inducing agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116138845\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4354\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4354|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/41/17044\" title=\"diagnostic image 1\">",
"      Carmustine lung fibrosis PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/57/20368\" title=\"diagnostic image 2\">",
"      Carmustine lung fibrosis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4354|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/0/11278\" title=\"figure 1\">",
"      FVC carmustine lung fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4354|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/13/27860\" title=\"picture 1\">",
"      Carmustine lung fibrosis Gross",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37415?source=related_link\">",
"      Busulfan-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41380?source=related_link\">",
"      Chlorambucil-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=related_link\">",
"      Cyclophosphamide pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=related_link\">",
"      Diffusing capacity for carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=related_link\">",
"      Pulmonary complications after allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_42_28328="Depression in adults: Psychodynamic psychotherapy";
var content_f27_42_28328=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Depression in adults: Psychodynamic psychotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/42/28328/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28328/contributors\">",
"     Glen Gabbard, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28328/contributors\">",
"     Valdesha Ball, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/42/28328/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28328/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/42/28328/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28328/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/42/28328/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 31, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H16008077\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many types of psychotherapy indicated for the treatment of depression, including psychodynamic psychotherapy.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psychodynamic psychotherapy is based upon the idea that childhood experiences, past unresolved conflicts, and previous relationships significantly influence an individual&rsquo;s current situation in life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, adult relationships are understood to be a byproduct of unconscious patterns that begin in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/2\">",
"     2",
"    </a>",
"    ]. Psychodynamic psychotherapy uncovers the unconscious patterns of object relations (interpersonal relationships), conflicts, and desires that cause depression.",
"   </p>",
"   <p>",
"    This topic reviews psychodynamic psychotherapy for treating mild to moderate depression in adults. The initial treatment of depression; treatment of resistant depression; diagnosis of depression, prognosis of depression; treatment of late-life depression; and epidemiology, pathogenesis, and neurobiology of depression are discussed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=see_link\">",
"       \"Unipolar depression in adults: Prognosis and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=see_link\">",
"       \"Diagnosis and management of late-life depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=see_link\">",
"       \"Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16008084\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treating patients with psychodynamic psychotherapy is based upon the nature of the patient's depression and psychological characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mild to moderate depression can be treated with psychodynamic therapy alone. Treatment studies evaluating the efficacy of psychodynamic psychotherapy for treating depression have largely been conducted with mild to moderately depressed patients. (See",
"      <a class=\"local\" href=\"#H189322022\">",
"       'Evidence of efficacy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with moderate to severe depression, especially moderate to severe suicidal ideation or moderate to severe neurovegetative symptoms (decreased sleep, appetite, and energy), require pharmacotherapy in addition to psychodynamic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .) The patient&rsquo;s personality, motivation, and level of social and occupational functioning determine whether a depressed patient is a good candidate for psychodynamic psychotherapy (",
"      <a class=\"graphic graphic_table graphicRef58113 \" href=\"UTD.htm?5/17/5404\">",
"       table 1",
"      </a>",
"      ). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized trial found that better outcomes occurred when patients were systematically selected for psychodynamic therapy on the basis of specific criteria that included diagnosis, the patient&rsquo;s therapeutic goals (eg, integrating unconscious aspects of behavior), and patient preference, compared with not using these criteria prior to treatment with psychodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87035393\">",
"    <span class=\"h1\">",
"     THEORETICAL FOUNDATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychodynamic psychotherapy requires an understanding that the past repeats itself in the present in ways that are painful for the patient. Therapy is based upon the theory that adult relationships are governed by unconscious conflicts, desires, thoughts, feelings, and patterns of relating to others, which are ingrained from childhood.",
"   </p>",
"   <p>",
"    The goal of treatment is to make these unconscious, repetitive patterns more conscious by studying how they emerge in the relationship between the patient and the clinician. The clinician identifies and interprets the patient&rsquo;s transference and resistance. In addition, the clinician&rsquo;s countertransference is also used to understand the unconscious conflicts that occur in the patient&rsquo;s life outside of therapy. (See",
"    <a class=\"local\" href=\"#H87035537\">",
"     'Fundamental concepts and processes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87035464\">",
"    <span class=\"h2\">",
"     Etiology of depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different psychodynamic theorists have conceptualized the origin of depression in various ways [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Depression may be due to psychosocial issues, stressors, or internal feelings and needs. These various causal factors are not mutually exclusive, and there are other possible etiologies.",
"   </p>",
"   <p>",
"    Social issues may lead to depression. One hypothesis is that depression arises from anxiety and guilt related to having harmed loved ones. Another hypothesis is that the patient is living her life for others instead of herself, a concept referred to as the \"dominant other.\" For these patients, success in life is closely connected to eliciting the desired response from the dominant other.",
"   </p>",
"   <p>",
"    Stressors and what they mean to the patient may be involved in the onset of depressive syndromes. As an example, stressors involving both loss and humiliation are more likely to cause depression than events involving loss alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One psychodynamic model identifies two types of depression based upon internal feelings and needs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/10\">",
"     10",
"    </a>",
"    ]. The \"anaclitic\" type is characterized by feelings of helplessness, weakness, and loneliness that are linked to chronic fears of being unprotected, alone, and abandoned. Patients with this type of depression want to be loved, protected, and nurtured. They use the defense mechanisms of disavowal, displacement, and denial. The \"introjective\" type of depression occurs in patients who are primarily focused on their own self-development. Relationships with others are regarded as secondary. These patients tend to be perfectionistic, competitive, and driven to achievement. Depression may be due to disparity (conflict) between a patient's ideals and reality, ie, the patient believes that he has not held himself up to a high standard. These patients use the defense mechanisms of reaction formation, rationalization, and intellectualization (",
"    <a class=\"graphic graphic_table graphicRef81648 \" href=\"UTD.htm?17/60/18381\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87035537\">",
"    <span class=\"h1\">",
"     FUNDAMENTAL CONCEPTS AND PROCESSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychodynamic therapy is based upon the idea that there are unconscious mental states and processes, including transference, countertransference, defense mechanisms, and resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3425386\">",
"    <span class=\"h2\">",
"     Unconscious",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large part of mental functioning is driven by the unconscious [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/4\">",
"     4",
"    </a>",
"    ]. &nbsp;The unconscious is a reservoir of repressed content that is kept out of awareness because it creates conflict. According to topographic model, mental functioning consists of three domains: conscious, preconscious, and unconscious. &nbsp;It is difficult to become aware of unconscious material. &nbsp;However, preconscious content can be retrieved by simply shifting one&rsquo;s attention. &nbsp;The aim of psychodynamic therapy is to bring unconscious material to the surface so it can be examined and understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H882460\">",
"    <span class=\"h2\">",
"     Transference",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transference is the unconscious displacement onto the clinician of feelings, thoughts, wishes, and qualities associated with an important individual from the patient&rsquo;s past [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/2\">",
"     2",
"    </a>",
"    ]. As an example, the patient may unconsciously respond to the clinician in the same manner that the patient responded to an authority figure from the past, such as a parent. Transference thus represents the unconscious re-creation of a past relationship in the present. In addition, transference may involve multiple prior relationships, or ongoing relationships that began prior to the relationship between the patient and clinician.",
"   </p>",
"   <p>",
"    Whereas the original definition assumed that the feelings and thoughts were transferred and superimposed upon the clinician without much change, it is now believed that the clinician&rsquo;s behavior influences how the patient responds to the clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/2\">",
"     2",
"    </a>",
"    ]. Transference to the clinician is thus based partly upon individuals from the patient&rsquo;s past and partly upon the real characteristics of the clinician. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H882475\">",
"    <span class=\"h2\">",
"     Countertransference",
"    </span>",
"    &nbsp;&mdash;&nbsp;Countertransference is the clinician&rsquo;s conscious and unconscious feelings and thoughts about the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. It consists of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The clinician&rsquo;s feelings and thoughts about an individual from a previous relationship that are displaced onto the patient",
"     </li>",
"     <li>",
"      Feelings and thoughts induced in the clinician by the patient&rsquo;s behavior",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recognizing countertransference provides data that help the clinician to discern problems that the patient encounters in relationships outside the therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/12\">",
"     12",
"    </a>",
"    ]. Other people probably respond to the patient in a manner similar to the clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20761777\">",
"    <span class=\"h2\">",
"     Defense mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients unconsciously use defense mechanisms to cope with anxiety and conflict, preserve self-esteem, and maintain a sense of control in interactions with people who are important to the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/2\">",
"     2",
"    </a>",
"    ]. Defense mechanisms are usually divided into two classes, those that are primitive or immature, and those that are higher-level. It is worth noting that everyone uses primitive defenses, such as denial and splitting, when under stress (",
"    <a class=\"graphic graphic_table graphicRef81648 \" href=\"UTD.htm?17/60/18381\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H882524\">",
"    <span class=\"h2\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another principle of psychodynamic psychotherapy is that patients may be ambivalent about getting better and resist the clinician&rsquo;s effort to help. The unconscious process of resistance may take many forms, such as the patient refusing to speak about a painful issue, or periodically showing late for appointments, or not at all. Resistance may indicate that the patient feels guilty about something, the depression is deserved, and that the patient should not get better.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16008112\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should assess patients to determine whether psychodynamic psychotherapy is indicated. In addition, the clinician should examine past and ongoing stressors, the patient&rsquo;s behavioral patterns in relationships, and defense mechanisms that the patient uses to reduce anxiety and control conflict. Clinicians continue to assess patients throughout the entire treatment process. A skillful assessment requires psychiatric training and experience.",
"   </p>",
"   <p>",
"    The first step in the assessment is to determine whether the patient can benefit from psychodynamic psychotherapy. Clinicians should assess the patient&rsquo;s personality characteristics, motivation, judgment, capacities and psychological mindedness, psychosocial functioning, and insight (",
"    <a class=\"graphic graphic_table graphicRef58113 \" href=\"UTD.htm?5/17/5404\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The clinician should identify stressors in the patient's life and what each stressor means to the patient. The clinician will later examine if the stressors fit into a particular pattern. Stressors involving trauma may reawaken earlier losses or trauma that had been forgotten.",
"   </p>",
"   <p>",
"    Information is gathered on developmental deficits, which may have occurred in the form of early losses, abuse, neglect, or parental failure to respond empathically to the patient&rsquo;s childhood needs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/2\">",
"     2",
"    </a>",
"    ]. The clinician analyzes how these losses or trauma impact the patient's relational style and overall behavior.",
"   </p>",
"   <p>",
"    Behavioral patterns are observed and familiar themes in relationships are explored. As an example, a 59 year-old woman discussed with her clinician that she repeatedly finds herself resenting her friends and family members when they do not help her in time of need. The clinician pointed out that the patient overextends herself in relationships to the point of self-sacrifice, and encouraged her to explore if the sacrifices she makes contribute to her pervasive resentment.",
"   </p>",
"   <p>",
"    Biological predispositions as well as intergenerational reenactment patterns are considered.",
"   </p>",
"   <p>",
"    The patient's personality characteristics are also assessed to see if they contribute to the depressive syndrome. As an example, perfectionism may make patients feel it is impossible to reach their goals, leading to hopelessness and worthlessness.",
"   </p>",
"   <p>",
"    The patient&rsquo;s typical defense mechanisms are assessed to understand how the patient copes with anxiety and conflict [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/2\">",
"     2",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef81648 \" href=\"UTD.htm?17/60/18381\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H20761777\">",
"     'Defense mechanisms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16008119\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should follow certain general principles in providing psychodynamic therapy. &nbsp;In addition, a number of specific interventions are used. However, treatment depends less upon any specific maneuver and more upon the therapeutic alliance (relationship) between the patient and clinician.",
"   </p>",
"   <p>",
"    The relationship between the clinician and patient starts at the beginning of the first interview or session. Thus, treatment begins with the first session, even though the first few sessions are focused primarily upon assessing the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114332\">",
"    <span class=\"h2\">",
"     General treatment principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychodynamic psychotherapy is based upon the following principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians should elicit a narrative of the patient's life during the history-taking and listen to how the patient formulates the experience of depression. In addition, the clinician should ask about stressors that have occurred and are ongoing, and explore the underlying meaning that a stressor may have to the patient.",
"     </li>",
"     <li>",
"      The clinician and patient need to negotiate the goals of treatment. While resolution of the depressive syndrome is an explicit goal, the broader goal is change in personality characteristics that leave the patient vulnerable to depression. The focus is upon developing awareness of unconscious feelings, thoughts, and behaviors that cause depression and relationship problems [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The clinician looks for stressors that generally precede depression (eg, breakup of a relationship) and characterological tendencies (eg, perfectionistic expectations for oneself) that can lead to depression.",
"     </li>",
"     <li>",
"      As psychotherapy proceeds, the clinician helps the patient understand the origins of the depressive syndrome, by interpreting and explaining repetitive patterns and unconscious conflicts that occur within relationships outside the therapy and in the relationship with the clinician. In addition, the clinician points out the patient&rsquo;s use of defense mechanisms, and explores how these defenses may be helpful (eg, prevent overwhelming anxiety), as well as detrimental (eg, prevent self-examination on the part of the patient). The patient's improvement is directly linked to gaining insight into these patterns, conflicts, and defenses.",
"     </li>",
"     <li>",
"      The clinician observes how the patient relates to the clinician. As an example, the patient may ask questions about the clinician, as part of the patient&rsquo;s desire or fantasy of creating a social relationship with the clinician that extends beyond their professional relationship. &nbsp;",
"     </li>",
"     <li>",
"      Clinicians should minimize disclosing information about themselves in order to maintain the focus of treatment upon the patient. In addition, the unconscious process of transference is more likely to occur if the patient has less tangible information about the clinician. Thus, questions posed by a patient should be explored for their underlying meaning, rather than directly answered. However, revealing a current feeling or discussing a common interest with the patient as part of spontaneous conversation may enhance the therapeutic relationship. (See",
"      <a class=\"local\" href=\"#H882460\">",
"       'Transference'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H114251\">",
"       'Therapeutic alliance'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The clinician determines how the patient unconsciously resists the clinician&rsquo;s efforts to help. In addition, the clinician monitors countertransference that occurs in response to the patient&rsquo;s resistance and to other aspects of the patient&rsquo;s behavior. (See",
"      <a class=\"local\" href=\"#H882524\">",
"       'Resistance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H882475\">",
"       'Countertransference'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment is usually provided in an individual format. However, psychodynamic therapy has been adapted for use in groups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychodynamic therapy can be either time-limited or open-ended. Time-limited therapy generally ranges from 12 to 24 sessions that are provided once per week over three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Open-ended, long-term therapy is provided at a frequency of one or two sessions per week. Longer-term therapy is indicated when brief therapy is not effective and the presence of longstanding personality traits complicates recovery from the depressive syndrome. The duration of each session is approximately 50 minutes.",
"   </p>",
"   <p>",
"    If one clinician is providing psychodynamic psychotherapy and another clinician is prescribing antidepressant medication, they need to work together as members of the same treatment team. The clinicians must have an agreement with each other and with the patient that there are no secrets between the two clinicians, and that the clinicians will regularly communicate about any concerns they have.",
"   </p>",
"   <p>",
"    Clinicians who lack experience with psychodynamic psychotherapy should receive supervision from a clinician who has expertise with this treatment.",
"   </p>",
"   <p>",
"    Psychodynamic psychotherapy developed from psychoanalysis, but the two treatments differ in some ways. Whereas in psychoanalysis patients lie on a couch, psychodynamic therapy calls for patients to be seated and facing the therapist. In addition, psychodynamic therapy does not emphasize using dreams to study the patient&rsquo;s unconscious processes, as is done in psychoanalysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114251\">",
"    <span class=\"h2\">",
"     Therapeutic alliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic relationship between the patient and clinician is more important than any specific technique in producing a positive outcome. Extensive research shows that a strong therapeutic alliance is associated with good outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/2,16,17\">",
"     2,16,17",
"    </a>",
"    ]. A strong therapeutic alliance is defined by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient feels attached to the clinician",
"     </li>",
"     <li>",
"      The patient feels the therapist is helpful",
"     </li>",
"     <li>",
"      The patient and clinician feel a sense of mutual collaboration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician should work to develop the therapeutic alliance from the first session by [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Listening closely and sensitively to the patient",
"     </li>",
"     <li>",
"      Conveying warmth, trust, and understanding",
"     </li>",
"     <li>",
"      Addressing both emotional and cognitive material",
"     </li>",
"     <li>",
"      Conducting treatment in a nonjudgmental manner",
"     </li>",
"     <li>",
"      Identifying and pursuing new clinical issues",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ruptures in the alliance can occur, marked by deterioration in the relationship between the patient and clinician, diminished collaboration, and poor communication [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/2\">",
"     2",
"    </a>",
"    ]. Clinicians should identify and explore these problems. Successful resolution is more likely to occur if clinicians can acknowledge their contribution to the rupture, rather than simply blaming it entirely upon the patient.",
"   </p>",
"   <p>",
"    Repairing a rupture in the therapeutic alliance can provide the patient with a corrective emotional experience, in which the patient is exposed to and tolerates an emotional situation that was previously intolerable. Thus, the rupture and repair provide the patient with an opportunity to confront previously difficult situations, within the more favorable circumstance of the therapeutic relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/18\">",
"     18",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114301\">",
"    <span class=\"h2\">",
"     Therapeutic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic change and resolution of the depressive syndrome occur through use of techniques that form a continuum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. At one end are interventions that increase the patient&rsquo;s insight through exploration and interpretation of the patient&rsquo;s defenses and behavior. The other end consists of interventions that directly support the patient and maintain adaptive defense mechanisms. Assessment of the patient reveals how to balance the need for both interpretive and supportive comments. As therapy progresses, the clinician should emphasize interpretation and other interventions intended to increase insight into unconscious processes (",
"    <a class=\"graphic graphic_table graphicRef81648 \" href=\"UTD.htm?17/60/18381\">",
"     table 2",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    The specific interventions listed below begin with those that are intended to promote insight, and end with interventions aimed at directly supporting the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114409\">",
"    <span class=\"h3\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An explanatory statement that links a feeling, thought, behavior, or symptom to its unconscious meaning or origin. Thus, interpretations involve underlying motivations. As an example, the clinician may state: You seem to hold yourself back from succeeding because you worry that your mother will be envious and retaliate against you.",
"   </p>",
"   <p>",
"    Patients are more likely to seriously consider an interpretation if it is presented as a possibility or hypothesis, rather than a definitive conclusion. In addition, interpretations should be made judiciously and sparingly, after the clinician has gathered enough evidence to substantiate them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114416\">",
"    <span class=\"h3\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comment that calls attention to something that the patient is not aware of, such as nonverbal behavior, a pattern in the therapeutic process, or a sequence of moving away from certain topics of discussion. However, an observation does not attempt to provide an explanation, as does an interpretation. As an example, a clinician may make the observation, &ldquo;Have you noticed that when we begin speaking about your mother, you change the topic?&rdquo; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114423\">",
"    <span class=\"h3\">",
"     Confrontation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calls attention to something that the patient does not want to accept or think about. It differs from observation in that confrontation addresses conscious material that the patient is avoiding. Confrontation may also involve setting limits with a patient who may attempt to cross the boundaries of the relationship between the clinician and patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114430\">",
"    <span class=\"h3\">",
"     Clarification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reformulates or pulls together what the patient is saying into a more coherent view of what the patient is communicating in a vague and uncertain manner. The clinician summarizes or repackages what the patient has spoken about, so that both the patient and clinician are clear about the patient&rsquo;s feelings and thoughts. A clarification is often posed as a question, such as, &ldquo;I wonder if what you really are saying is that you&rsquo;re not sure if you want to remain in your current job?&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114437\">",
"    <span class=\"h3\">",
"     Encouragement to elaborate",
"    </span>",
"    &nbsp;&mdash;&nbsp;An open-ended comment asking for more information. As an example, &ldquo;You just mentioned your father&rsquo;s family. Please tell me more about them.&rdquo; Ideally, patients trust the clinician and will not censor or filter what they are saying.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114444\">",
"    <span class=\"h3\">",
"     Empathic validation",
"    </span>",
"    &nbsp;&mdash;&nbsp;This intervention demonstrates a clinician's empathic understanding of the patient's internal state by validating the patient's subjective experience. Many patients, while growing up, have had parents or other adults invalidate or deny their internal experience, being told, for example, &ldquo;You have no right to feel that way.&rdquo; Empathic validation assures a patient that their feelings and responses are legitimate, given what the patient has experienced. As an example, a clinician may state, &ldquo;It&rsquo;s understandable that you&rsquo;re reluctant to get close to people after being hurt in previous relationships.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114451\">",
"    <span class=\"h3\">",
"     Psychoeducation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician teaches the patient about the nature of depression, goals of therapy, and limits of therapy. In a broader sense, the clinician uses psychodynamic therapy to teach the patient about him or herself, and how to examine one&rsquo;s own behavior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114458\">",
"    <span class=\"h3\">",
"     Advice and praise",
"    </span>",
"    &nbsp;&mdash;&nbsp;These reinforce and prescribe certain activities through explicit suggestions or compliments. Advice may be necessary for patients who are in crisis and unsure of how to proceed. Praise may be offered for the patient coming up with original insights that the clinician had not considered, and for changing their behavior in ways that are consistent with the patient&rsquo;s goals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364006067\">",
"    <span class=\"h2\">",
"     Therapeutic strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are different strategies that clinicians can use to help the depressed patient become more self-aware and work through repetitive, painful patterns and problems [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/2\">",
"     2",
"    </a>",
"    ]. One useful model is the Core Conflictual Relationship Theme [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/19\">",
"     19",
"    </a>",
"    ]. It consists of three related phenomena:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient's wishes, expectations, and fantasies about other people",
"     </li>",
"     <li>",
"      The perceived reaction of other people to these wishes, expectations and fantasies",
"     </li>",
"     <li>",
"      The patient's response to the imagined reaction of the other",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician identifies the core theme in the patient's stories about childhood and adult life, and observes its emergence in the therapeutic relationship.",
"   </p>",
"   <p>",
"    An example of an interpretation based upon this model is the following, which involves a patient who is stuck and unable to complete a major task, such as completing graduate school: &ldquo;After getting to know you, I can see that you always imagined that you had to be perfect to please your dad, but you assumed that nothing you did would ever satisfy him, and he would be disappointed in you and always expect more. As a result, you gave up and decided not to try anymore.&rdquo; The clinician might also help the patient see how that fantasy plays out in the therapeutic relationship, with the patient assuming that the clinician expects perfection from the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3425393\">",
"    <span class=\"h1\">",
"     TERMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is terminated for several reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The goals have been completed.",
"     </li>",
"     <li>",
"      Therapy is no longer feasible. As an example, the patient or clinician may relocate.",
"     </li>",
"     <li>",
"      An impasse occurs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians need to temper their expectation for change upon the part of the patient and not impose goals upon the patient. Successful treatment helps patients internalize the process of inquiry that occurs in treatment, and enables patients to examine themselves and continue the work of therapy on their own.",
"   </p>",
"   <p>",
"    Euthymic patients should be told that even though psychotherapy helped them, depression is often a recurring illness. Patients should understand that if they notice early, prodromal depressive symptoms, &ldquo;the door is always open&rdquo; to resume treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20761851\">",
"    <span class=\"h1\">",
"     CONTINUING CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may need to continue pharmacotherapy to prevent relapse of the depressive syndrome, despite successful treatment with psychodynamic psychotherapy. If the same clinician who provided psychotherapy continues to provide pharmacotherapy, the clinician should schedule regular follow-up meetings to assess the patient for early signs and symptoms of relapse. Some psychodynamic interventions are also helpful at those regular follow-up appointments to maintain the insight gained through the therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189322022\">",
"    <span class=\"h1\">",
"     EVIDENCE OF EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research studies indicate that psychodynamic psychotherapy effectively treats depression in adults.",
"   </p>",
"   <p>",
"    Psychotherapy trials, like pharmacotherapy trials, are methodologically variable. Some psychotherapy trials are rigorous and specify a priori hypotheses and analytic tests, use active psychotherapy comparators that control for the nonspecific aspects of psychotherapy, use standardized diagnostic criteria and outcome measures, carefully blind outcome ratings, develop manuals for the psychotherapies that are studied and measure adherence, and stratify patients on predetermined risk variables. Less meticulous studies use open-label designs, less rigorous comparators (eg, treatment as usual or waiting lists), or fail to adequately blind outcome ratings. Although it is commonly believed that blinding of patients in psychotherapy is less successful compared with pharmacotherapy trials, this has never been studied.",
"   </p>",
"   <p>",
"    Meta-analyses appear to overestimate the clinical effect for nearly all types of psychotherapy in treating depression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. These inflated clinical effects seem to be the result of publication bias and study quality. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189321935\">",
"    <span class=\"h2\">",
"     Psychodynamic psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies suggest that psychodynamic therapy is effective for mild to moderate depression.",
"   </p>",
"   <p>",
"    A meta-analysis examined improvement of depression rating scale scores in 23 studies with 1365 depressed patients treated with time-limited psychodynamic psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/13\">",
"     13",
"    </a>",
"    ]. Eleven studies compared psychodynamic therapy with another type of psychotherapy, five studies compared psychodynamic psychotherapy with a control condition such as waiting list or treatment as usual, and the remaining seven studies included only psychodynamic psychotherapy. The analyses found a significant, clinically large effect favoring psychodynamic therapy over the control condition. In addition, large changes from pre-treatment to post-treatment occurred in patients who received psychodynamic therapy, both in studies that permitted use of antidepressants and those that did not, and these changes were maintained for up to one year.",
"   </p>",
"   <p>",
"    Another meta-analysis of 23 randomized trials with 1431 patients found that improvement of depression rating scale scores was significantly greater for patients who received time-limited psychodynamic psychotherapy (less than 40 sessions), compared with patients in control conditions (waiting list, minimal treatment designated as placebo psychotherapy, or treatment as usual). The clinically moderate effect was maintained in medium- and long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189321942\">",
"    <span class=\"h3\">",
"     Compared with other psychotherapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;For treatment of mild to moderate depression, there is little or no difference between psychodynamic psychotherapy and other types of psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. Specifically, the evidence suggests that the efficacy of psychodynamic therapy is similar to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Behavioral activation therapy",
"     </li>",
"     <li>",
"      Cognitive-behavioral therapy",
"     </li>",
"     <li>",
"      Interpersonal therapy",
"     </li>",
"     <li>",
"      Problem-solving therapy",
"     </li>",
"     <li>",
"      Social skills training",
"     </li>",
"     <li>",
"      Supportive psychotherapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis examined outcome in 23 studies with 1365 depressed patients treated with time-limited psychodynamic psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients who received other types of psychotherapy (usually a form of cognitive-behavioral psychotherapy) improved significantly more than patients treated with psychodynamic therapy. However, the clinical effect favoring the alternative therapies was small, and the differences disappeared at follow-up 3 months and 12 months post-treatment.",
"   </p>",
"   <p>",
"    Another meta-analysis of 53 randomized trials (2757 patients with mild to moderate depression) compared psychodynamic psychotherapy with all other psychotherapies combined together, and found no significant difference [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/1\">",
"     1",
"    </a>",
"    ]. Drop-out from psychodynamic therapy and from all other psychotherapies was also similar.",
"   </p>",
"   <p>",
"    Different meta-analyses of randomized trials have specifically compared psychodynamic psychotherapy and cognitive-behavioral therapy, and found no significant difference in improvement of depressive symptoms and social functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/1,23\">",
"     1,23",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189322128\">",
"    <span class=\"h3\">",
"     Compared with pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with mild to moderate depression, time-limited psychodynamic psychotherapy may be as effective as pharmacotherapy.",
"   </p>",
"   <p>",
"    A randomized trial of 51 patients with mild or moderate major depression found that remission occurred in a similar number of patients treated with either psychodynamic psychotherapy (one session per week) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    (20 to 40 mg per day) for 16 weeks (57 versus 68 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/24\">",
"     24",
"    </a>",
"    ]. Improvement in social and occupational functioning was also similar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16008140\">",
"    <span class=\"h2\">",
"     Psychodynamic psychotherapy plus pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have tested the efficacy of combining psychodynamic therapy with an antidepressant, either for treating acute depression, or as maintenance treatment for preventing recurrence of depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16008147\">",
"    <span class=\"h3\">",
"     Acute depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with acute depression, psychodynamic therapy plus pharmacotherapy may provide superior outcomes compared with pharmacotherapy alone. A randomized trial compared combination treatment (psychodynamic psychotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    ) with clomipramine alone, in 74 patients with unipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/25\">",
"     25",
"    </a>",
"    ]. Significantly fewer patients who received combination treatment met criteria for major depression at 10 weeks, compared with clomipramine alone (9 versus 28 percent). In addition, psychosocial functioning was significantly better in patients who received combination treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16008154\">",
"    <span class=\"h3\">",
"     Maintenance treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination treatment (psychodynamic therapy plus pharmacotherapy) may provide significantly better long-lasting effects compared to pharmacotherapy alone. A study enrolled patients with major depression who were successfully treated with six months of combination treatment (n = 41) or with pharmacotherapy alone (n = 51) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28328/abstract/26\">",
"     26",
"    </a>",
"    ]. All 92 remitted patients were then treated for an additional six months with pharmacotherapy alone, after which treatment was stopped and patients were prospectively followed for up to four years. Recurrence of major depression occurred in significantly fewer patients who had received combined treatment compared with patients who had received pharmacotherapy alone (27 versus 47 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16008161\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adult relationships are understood to be a byproduct of unconscious patterns that are ingrained from childhood. Psychodynamic psychotherapy involves identifying and making patients aware of these patterns in relationships, as well as unconscious meanings, conflicts, and desires that cause depression. (See",
"      <a class=\"local\" href=\"#H16008077\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychodynamic psychotherapy, without pharmacotherapy, can be used to treat patients with mild to moderate depression. The suitability of psychodynamic therapy is also based upon the patient&rsquo;s personality, motivation, and level of social and occupational functioning (",
"      <a class=\"graphic graphic_table graphicRef58113 \" href=\"UTD.htm?5/17/5404\">",
"       table 1",
"      </a>",
"      ).(See",
"      <a class=\"local\" href=\"#H16008084\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychodynamic psychotherapy emphasizes an understanding of unconscious conflict as it manifests itself in life outside the therapy as well as in the clinician-patient relationship through transference, countertransference, defense mechanisms, and resistance. The clinician interprets and helps the patient become aware of repetitive patterns and unconscious conflicts. Remission of the depressive syndrome is directly linked to the patient gaining insight into these patterns, conflicts, and defenses. &nbsp;(See",
"      <a class=\"local\" href=\"#H87035393\">",
"       'Theoretical foundation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H87035537\">",
"       'Fundamental concepts and processes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should assess patients to determine whether psychodynamic psychotherapy is suitable. In addition, the clinician should examine past and ongoing stressors and what they mean to the patient, the patient&rsquo;s behavioral patterns in relationships, and defense mechanisms that the patient uses to reduce anxiety and control conflict. (See",
"      <a class=\"local\" href=\"#H16008112\">",
"       'Assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General treatment principles for psychodynamic psychotherapy include asking about stressors and what they mean to the patient; observing how the patient relates to the clinician and unconsciously resists the clinician&rsquo;s efforts to help; helping the patient to become aware of unconscious feelings, thoughts, and behaviors that cause depression and relationship problems; and changing personality characteristics (eg, problematic defense mechanisms) that leave the patient vulnerable to depression (See",
"      <a class=\"local\" href=\"#H114332\">",
"       'General treatment principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The therapeutic relationship between the patient and clinician is more important than any specific technique in producing a positive outcome. A strong therapeutic alliance is defined by the following: the patient feels attached to the clinician, the patient feels the therapist is helpful, and the patient and clinician feel a sense of mutual collaboration. (See",
"      <a class=\"local\" href=\"#H114251\">",
"       'Therapeutic alliance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment involves the use of the following interventions: interpretation, observation, confrontation, clarification, encouragement to elaborate, empathic validation, psychoeducation, and advice and praise. (See",
"      <a class=\"local\" href=\"#H114301\">",
"       'Therapeutic interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One therapeutic strategy to help patients work through their problems is based upon identifying the patient's wishes, expectations, and fantasies about other people; the perceived reaction of other people to these wishes, expectations and fantasies; and the patient's response to the imagined reaction of the other. The clinician identifies these thoughts and feelings in the patient's stories about childhood and adult life, and observes their emergence in the therapeutic relationship. (See",
"      <a class=\"local\" href=\"#H364006067\">",
"       'Therapeutic strategy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychodynamic psychotherapy efficaciously treats mild to moderate depression. Controlled trials have found that psychodynamic therapy is significantly superior to control conditions (eg, waiting list or treatment as usual), and is comparable to other types of psychotherapy (eg, cognitive-behavioral therapy or interpersonal therapy). (See",
"      <a class=\"local\" href=\"#H189322022\">",
"       'Evidence of efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/1\">",
"      Cuijpers P, van Straten A, Andersson G, van Oppen P. Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. J Consult Clin Psychol 2008; 76:909.",
"     </a>",
"    </li>",
"    <li>",
"     Gabbard, GO. Techniques of psychodynamic psychotherapy. In: Textbook of  Psychotherapeutic Treatments, Gabbard, GO (Eds), American Psychiatric Publishing, Washington, DC 2009. p.43.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/3\">",
"      Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010; 71 Suppl E1:e04.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/4\">",
"      Watzke B, R&uuml;ddel H, J&uuml;rgensen R, et al. Effectiveness of systematic treatment selection for psychodynamic and cognitive-behavioural therapy: randomised controlled trial in routine mental healthcare. Br J Psychiatry 2010; 197:96.",
"     </a>",
"    </li>",
"    <li>",
"     Freud, S. Mourning and melancholia (1917). In: The Standard Edition of the Complete Psychological Works of Sigmund Freud, 14, Translated and edited by Strachey J. Hogarth Press (Ed), London 1963. p.237.",
"    </li>",
"    <li>",
"     Klein, M. Mourning and its relation to manic-depressive states (1940). In: Love, Guilt and Reparation and Other Works 1921-1945, Free Press, New York 1975. p.344.",
"    </li>",
"    <li>",
"     Bibring, E. The mechanism of depression. In: Affective Disorders: Psychoanalytic Contributions to Their Study, Greenacre P. International Universities Press (Ed), New York 1953. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/8\">",
"      Arieti S. Psychotherapy of severe depression. Am J Psychiatry 1977; 134:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/9\">",
"      Kendler KS, Hettema JM, Butera F, et al. Life event dimensions of loss, humiliation, entrapment, and danger in the prediction of onsets of major depression and generalized anxiety. Arch Gen Psychiatry 2003; 60:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/10\">",
"      Blatt SJ. The differential effect of psychotherapy and psychoanalysis with anaclitic and introjective patients: the Menninger Psychotherapy Research Project revisited. J Am Psychoanal Assoc 1992; 40:691.",
"     </a>",
"    </li>",
"    <li>",
"     Dewan, M, Weerasekera, P, Stormon, L. Techniques of Brief Psychodynamic Psychotherapy. In: Textboof of Psychotherapeutic Treatments, Gabbard GO (Ed), American Psychiatric Publishing, Washington, DC 2009. p.69.",
"    </li>",
"    <li>",
"     Gabbard, GO, Bennett, T. Psychoanalytic and psychodynamic psychotherapy for depression and dysthymia. In: APPI Textbook of Mood Disorders, Stein, D, Kupfer, DJ, Schatzberg, AJ (Eds), APPI, Arlington, VA 2005. p.389.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/13\">",
"      Driessen E, Cuijpers P, de Maat SC, et al. The efficacy of short-term psychodynamic psychotherapy for depression: a meta-analysis. Clin Psychol Rev 2010; 30:25.",
"     </a>",
"    </li>",
"    <li>",
"     Gabbard, GO. Long-Term Psychodynamic Psychotherapy: a Basic Text, 2nd, American Psychiatric Publishing, Arlington VA 2010.",
"    </li>",
"    <li>",
"     Leichsenring, F. Applications of psychodynamic psychotherapy to specific disorders: Efficacy and indications. In: Textbook of Psychotherapeutic Treatments, Gabbard, G (Eds), American Psychiatric Publishing, Arlington, VA 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/16\">",
"      Horvath AO, Luborsky L. The role of the therapeutic alliance in psychotherapy. J Consult Clin Psychol 1993; 61:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/17\">",
"      Zuroff DC, Blatt SJ. The therapeutic relationship in the brief treatment of depression: contributions to clinical improvement and enhanced adaptive capacities. J Consult Clin Psychol 2006; 74:130.",
"     </a>",
"    </li>",
"    <li>",
"     Winston, A, Goldstein, M. Theory of supportive psychotherapy. In: Textbook of Psychotherapeutic Treatments, Gabbard GO (Ed), American Psychiatric Publishing, Washington, DC 2009. p.393.",
"    </li>",
"    <li>",
"     Luborsky, L. Principles of Psychoanalytic Psychotherapy: a manual for supportive-expressive treatment, Basic Books, New York 1984.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/20\">",
"      Cuijpers P, van Straten A, Bohlmeijer E, et al. The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size. Psychol Med 2010; 40:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/21\">",
"      Cuijpers P, Smit F, Bohlmeijer E, et al. Efficacy of cognitive-behavioural therapy and other psychological treatments for adult depression: meta-analytic study of publication bias. Br J Psychiatry 2010; 196:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/22\">",
"      Abbass AA, Hancock JT, Henderson J, Kisely S. Short-term psychodynamic psychotherapies for common mental disorders. Cochrane Database Syst Rev 2006; :CD004687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/23\">",
"      Leichsenring F. Comparative effects of short-term psychodynamic psychotherapy and cognitive-behavioral therapy in depression: a meta-analytic approach. Clin Psychol Rev 2001; 21:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/24\">",
"      Salminen JK, Karlsson H, Hietala J, et al. Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: a randomized comparative study. Psychother Psychosom 2008; 77:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/25\">",
"      Burnand Y, Andreoli A, Kolatte E, et al. Psychodynamic psychotherapy and clomipramine in the treatment of major depression. Psychiatr Serv 2002; 53:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28328/abstract/26\">",
"      Maina G, Rosso G, Bogetto F. Brief dynamic therapy combined with pharmacotherapy in the treatment of major depressive disorder: long-term results. J Affect Disord 2009; 114:200.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14689 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_42_28328=[""].join("\n");
var outline_f27_42_28328=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16008161\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16008077\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16008084\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87035393\">",
"      THEORETICAL FOUNDATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87035464\">",
"      Etiology of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87035537\">",
"      FUNDAMENTAL CONCEPTS AND PROCESSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3425386\">",
"      Unconscious",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H882460\">",
"      Transference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H882475\">",
"      Countertransference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20761777\">",
"      Defense mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H882524\">",
"      Resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16008112\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16008119\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114332\">",
"      General treatment principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114251\">",
"      Therapeutic alliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114301\">",
"      Therapeutic interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114409\">",
"      - Interpretation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114416\">",
"      - Observation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114423\">",
"      - Confrontation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114430\">",
"      - Clarification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114437\">",
"      - Encouragement to elaborate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114444\">",
"      - Empathic validation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114451\">",
"      - Psychoeducation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114458\">",
"      - Advice and praise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H364006067\">",
"      Therapeutic strategy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3425393\">",
"      TERMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20761851\">",
"      CONTINUING CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189322022\">",
"      EVIDENCE OF EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H189321935\">",
"      Psychodynamic psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H189321942\">",
"      - Compared with other psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H189322128\">",
"      - Compared with pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16008140\">",
"      Psychodynamic psychotherapy plus pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16008147\">",
"      - Acute depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16008154\">",
"      - Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16008161\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14689\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14689|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/17/5404\" title=\"table 1\">",
"      Characteristics of good candidates for psychodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/60/18381\" title=\"table 2\">",
"      Psychodynamic defense mechanisms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=related_link\">",
"      Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=related_link\">",
"      Unipolar depression in adults: Prognosis and course of illness",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_42_28329="CD3/T cell receptor complex disorders causing immunodeficiency";
var content_f27_42_28329=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   CD3/T cell receptor complex disorders causing immunodeficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/42/28329/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28329/contributors\">",
"     Zuhair K Ballas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/42/28329/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28329/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/42/28329/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28329/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/42/28329/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TCR complex and its associated molecules are essential for T cell ontogeny and proper function of mature T cells. Deficiency in one of these components may result in major T cell deficiency or dysfunction. The clinical presentation of these defects varies widely, depending upon the severity of the genotypic abnormality. All of these immunodeficiencies are rare.",
"   </p>",
"   <p>",
"    A brief review of T cell receptor (TCR) biology is first presented in this topic review to better understand disorders of the TCR complex that are associated with immunodeficiency. Detailed discussions of these topics are presented separately. Immunodeficiencies that result from defects in individual TCR complex components are then reviewed. Idiopathic CD4 lymphopenia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=see_link\">",
"     \"Antigen presenting cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30009?source=see_link\">",
"     \"Idiopathic CD4+ lymphocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF T CELL RECEPTOR BIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The T cell receptor (TCR) is a heterodimer, with approximately 95 percent of peripheral blood T cells possessing an alpha and a beta chain (TCR alpha-beta or TCR2) and the remainder a gamma and a delta chain (TCR gamma-delta or TCR1) (",
"    <a class=\"graphic graphic_figure graphicRef75287 \" href=\"UTD.htm?29/60/30670\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/1\">",
"     1",
"    </a>",
"    ]. TCR gamma-delta is more abundant in skin and intraepithelial lymphocytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TCR chains belong structurally to the Ig gene superfamily. Thus, TCR genes undergo V(D)J recombination. This event is dependent upon the function of recombinase activating genes 1 and 2 (RAG1 and RAG2) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=see_link&amp;anchor=H3#H3\">",
"     \"T cell receptor genetics\", section on 'T cell receptor gene organization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A protein must first be processed by antigen-presenting cells (APCs) for T cells to recognize a specific antigen. APCs degrade the target antigen into several peptides. These peptides are subsequently presented on the cell surface in the groove formed by either a class I or II major histocompatibility complex (MHC) molecule. The human leukocyte antigen (HLA) system is synonymous with the human major histocompatibility complex (MHC). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=see_link\">",
"     \"Antigen presenting cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antigens processed for presentation in the context of class I MHC must be transported to the endoplasmic reticulum (ER), where class I MHC is assembled. Two proteins, transporter associated with antigen processing (TAP) 1 and 2, are specifically required for this function. Once in the ER, the peptides associate with class I MHC, which is comprised of an alpha chain noncovalently associated with beta-2-microglobulin (B2M). A specific molecule called TAP-binding protein (TAPBP), also called tapasin, is involved in peptide loading during MHC class",
"    <span class=\"nowrap\">",
"     I/antigen",
"    </span>",
"    intracellular transport and expression (",
"    <a class=\"graphic graphic_figure graphicRef76821 \" href=\"UTD.htm?9/9/9363\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The appropriate T cell receptor (TCR) is capable of binding the peptide and MHC complex (",
"    <a class=\"graphic graphic_figure graphicRef53512 \" href=\"UTD.htm?37/38/38499\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63541 \" href=\"UTD.htm?6/23/6527\">",
"     figure 4",
"    </a>",
"    ). CD4 and CD8 act as accessory molecules; they determine whether a particular TCR binds to Class I or Class II MHC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CD8 binds to a non-polymorphic region of class I MHC",
"     </li>",
"     <li>",
"      CD4 binds to a non-polymorphic region of class II MHC",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TCR chains are also noncovalently linked to nonpolymorphic CD3. Four CD3 chains have been described in humans: epsilon, gamma, delta, and zeta. Signaling cascades are activated upon engagement of the",
"    <span class=\"nowrap\">",
"     TCR/CD3",
"    </span>",
"    complex. CD3 is important in transducing the signal that initiates a T cell activation and differentiation pathway via a motif in the cytoplasmic domain, called the immunoreceptor tyrosine-based activation motif or ITAM (",
"    <a class=\"graphic graphic_figure graphicRef79731 \" href=\"UTD.htm?35/48/36611\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link&amp;anchor=H4#H4\">",
"     \"The adaptive cellular immune response\", section on 'T cell activation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a number of molecules involved in early signal transduction, including Lck, Fyn, ZAP-70, and Syk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. ZAP-70 deficiency is discussed separately, as is the signaling cascade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42022?source=see_link\">",
"     \"ZAP-70 deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/25001?source=see_link\">",
"     \"T cell receptor signaling\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proper functioning of CD3, TCR, and the early signaling molecules triggers a distal cascade in the cell culminating in the activation of the Ras-MAPK pathway, induction of NF-AT, and activation of NF-kappa B, with subsequent proliferation, differentiation, and cytokine secretion. Deficiencies in this distal cascade are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/10?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): Specific defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPES OF DEFICIENCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple molecules associated with the function of the TCR. Defects in these molecules may result in major T cell deficiency or dysfunction. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Defects in TCR itself &mdash; TCR defects were initially presumed lethal, because no defects had been identified. However, a mutation in the TCR alpha subunit constant (TRAC) gene that causes a nonlethal combined immunodeficiency was identified.",
"     </li>",
"     <li>",
"      TCR chain V(D)J rearrangement &mdash; V(D)J rearrangement of the TCR requires RAG1 and RAG2. Thus, a deficiency in either enzyme may result in the absence of T cells (as well as B cells, since B cells also use these enzymes). Other disorders due to defects in V(D)J rearrangement include deficiencies in Artemis, DNA-ligase IV, Cernunnos, and DNA-protein kinase catalytic subunit (DNA-PKcs).",
"     </li>",
"     <li>",
"      T cell binding to peptide-MHC complex &mdash; Deficiency of MHC class I or class II may result in abnormal CD8 or CD4 function, respectively. MHC deficiency may also cause a lack of maturation of the corresponding T cell subset, because MHC is important for thymic selection.",
"     </li>",
"     <li>",
"      Noncovalent coupling of TCR to CD3 &mdash; CD3 chain deficiency may result in T cell dysfunction.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       TCR/CD3",
"      </span>",
"      triggered signaling cascade &mdash; Deficiency in the protein kinases, Lck, Fyn, or ZAP-70, may cause major T cell dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL IMMUNODEFICIENCY SYNDROMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14761190\">",
"    <span class=\"h2\">",
"     TCR alpha subunit constant (TRAC) deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two unrelated children from consanguineous families were identified with an identical mutation in the TRAC gene that leads to greatly reduced surface expression of the T cell receptor alpha-beta (TCR&alpha;&beta;) complex [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TCR&alpha;&beta;+ T cells were absent and TCR&gamma;&delta;+ T cells increased. Antibody responses to vaccines and autoantigens were normal. Both reported patients had hypereosinophilia and one had elevated IgE.",
"   </p>",
"   <p>",
"    These children presented at 6 and 15 months of age with recurrent respiratory tract infections, candidiasis, and gastroenteritis (Salmonella, Cryptosporidium, rotavirus) that responded to conventional treatment. They also had failure to thrive, immune dysregulation (eg, vitiligo, alopecia areata, eczema, and autoimmune hemolytic anemia), lymphadenopathy, and hepatomegaly.",
"   </p>",
"   <p>",
"    Both children successfully underwent transplantation from a matched sibling donor at six to seven years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Defects of V(D)J recombination",
"    </span>",
"    &nbsp;&mdash;&nbsp;RAG1 and RAG2 are needed for the successful V(D)J recombination of members of the immunoglobulin gene superfamily (which includes immunoglobulins and TCR chains). A complete deficiency of either enzyme results in severe combined immunodeficiency due to the lack of maturation of either T or B cells (T-B-NK+ SCID). RAG1 and RAG2 deficiencies are a rare cause of SCID. Several mutations have been reported including nonsense, missense, and deletional mutations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link\">",
"     \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other disorders due to defects in V(D)J recombination include deficiencies in Artemis, DNA ligase IV, Cernunnos, and DNA-PKcs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link\">",
"     \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     MHC (HLA) class I deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with MHC class I deficiency (Bare lymphocyte syndrome type I, MIM 604571) have defects in TAP1, TAP2, or tapasin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/6-15\">",
"     6-15",
"    </a>",
"    ]. The exact defect has not been identified in other patients with MHC class I deficiency. B2M deficiency induced in mutant mice results in the absence of class I on the cell surface, but no cases of immunodeficiency due to B2M mutations have been reported in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in the expression of MHC class I complexes have been classified into three groups. Due to the small number of patients in each of these groups, the exact pattern of inheritance of MHC class is not clear. The three groups are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals with decreased MHC class I expression (approximately 10 percent of normal) do not have an increased incidence of infections and appear to be asymptomatic. The very few individuals identified with this defect were discovered in the process of evaluating a sibling. In this setting, the probable defect is an abnormality in transcription of MHC class I [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/10,13,16\">",
"       10,13,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with severe reduction of MHC class I expression (1 to 3 percent of normal) are healthy during the first year of life. However, by late childhood, frequent upper and lower respiratory tract bacterial infections begin to occur, leading to bronchiectasis and conductive hearing loss [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Affected patients also have necrotizing granulomatous skin lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/18\">",
"       18",
"      </a>",
"      ]. Some with this particular phenotype have TAP1 or TAP2 deficiency.",
"     </li>",
"     <li>",
"      A less well characterized group of patients has a combined immunodeficiency phenotype, with recurrent bacterial, fungal, and parasitic infections in the first year of life. These patients have a severe decrease in surface expression of MHC class I alpha chain and B2M. The exact molecular deficiency has not been characterized, but transcription defects have been excluded [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/8,11,13,14\">",
"       8,11,13,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Laboratory features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with MHC I expression abnormalities exhibit decreased or absent MHC I expression on the cell surface and decreased NK cell killing activity. However, they have normal antibody-dependent cell-mediated cytotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/19\">",
"     19",
"    </a>",
"    ]. Defects of TAP1, TAP2, and tapasin are usually associated with low numbers of CD8+ T cells. This is an expected finding, since MHC I is needed for positive thymic selection of CD8+ T cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis is obtained by flow cytometry examination showing decreased MHC class I expression on the surface of peripheral blood mononuclear cells (PBMCs). Further genetic testing to determine if there are mutations in B2M, TAP1, or TAP2 is then undertaken.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of MHC class I deficiency is large. It includes other immunodeficiency syndromes (such as common variable immunodeficiency or ataxia telangiectasia) as well as other possible etiologies for granulomatous disease (such as chronic granulomatous disease, granulomatosis with polyangiitis [Wegener's], or midline granuloma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=see_link\">",
"     \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is directed at infection control. Early and prolonged use of antibiotics should be undertaken at the first sign of infection. Some patients have benefited from immune globulin therapy. Hematopoietic cell transplantation (HCT) has not been considered for MHC class I deficiency, because MHC class I expression is not restricted to hematopoietic cells; thus, HCT may not correct the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     MHC (HLA) class II deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;MHC class II deficiency (Bare lymphocyte syndrome type II), an autosomal recessive disease, has been reported in fewer than 80 patients worldwide. Both constitutive and induced MHC class II expressions are compromised.",
"   </p>",
"   <p>",
"    Four distinct genetic groups, called complementation groups, can be identified based upon four MHCII-specific transcription factors. The majority map to chromosome 19p12 (RFXANK). The other three defects map to 16p13 (MHC2TA gene or class II transactivator, CIITA, protein), 1q21.1-21.3 (RFX5), and 13q14 (RFXAP).",
"   </p>",
"   <p>",
"    These genetic groups can be simplified into two populations depending upon the presence of regulatory factor X (RFX). RFX is a DNA-binding protein complex that binds, in vitro, to the X box of Class II promoters. Patients from one group (whose defect maps to chromosome 16p13) have normal RFX expression, while the other three groups do not [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/20-23\">",
"     20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact molecular defects have not been identified in most patients, but are suspected to involve mutations in these MHCII promoter complex DNA-binding regulatory factors (CIITA, RFX5, RFXAP, and RFXANK). The majority of identified defects are RFXANK mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/24\">",
"     24",
"    </a>",
"    ]. A mutation in the regulatory factor X (RFX) complex subunit RFXAP was identified in several patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/25-27\">",
"     25-27",
"    </a>",
"    ] and mutations in RFX5 and MHC2TA (CIITA) have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Class II MHC deficiency generally results in a clinical picture of severe combined immune deficiency, since MHC II plays a pivotal role in the maturation and function of both T and B cells. However, milder cases have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients present with viral, bacterial, fungal,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    protozoal infections. Common disorders include pneumonitis, bronchitis, gastroenteritis, and septicemia. Infections usually start in the first year of life and are associated with failure to thrive, diarrhea, and malabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. A fatal case of vaccine-associated paralytic poliomyelitis was also reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Laboratory features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following laboratory findings are observed (",
"    <a class=\"graphic graphic_table graphicRef76313 \" href=\"UTD.htm?36/35/37435\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal number of B cells in peripheral blood",
"     </li>",
"     <li>",
"      Hypogammaglobulinemia",
"     </li>",
"     <li>",
"      Poor specific antibody responses",
"     </li>",
"     <li>",
"      Normal number of T cells in peripheral blood",
"     </li>",
"     <li>",
"      CD4 lymphopenia, with a proportional increase in CD8",
"     </li>",
"     <li>",
"      Normal in vitro T cell response to phytohemagglutinin (PHA)",
"     </li>",
"     <li>",
"      Decreased in vitro T cell response to antigens",
"     </li>",
"     <li>",
"      Complete absence of MHC II expression on B cells",
"     </li>",
"     <li>",
"      Slight decrease in MHC Class I expression",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Diagnosis and differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MHC class II deficiency is based upon the finding of absent MHC class II expression on PBMCs by flow cytometry. An attempt should then be made to identify the exact genetic defect. The differential diagnosis includes other immunodeficiency syndromes, with combined antibody and cellular immune abnormalities. Diagnostic criteria are shown in the figure (",
"    <a class=\"graphic graphic_table graphicRef57419 \" href=\"UTD.htm?4/50/4908\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy is supportive and is aimed at reducing infections with the administration of antibiotics and immune globulin therapy. Hematopoietic cell transplantation can be curative, although the success rate is lower than for other combined immunodeficiency diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/35\">",
"     35",
"    </a>",
"    ]. The chances for success are higher if the transplant is performed in the first two years of life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients generally die before five years of age without transplantation. Gene therapy is under investigation in mouse models of this disease, but there have been no human trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     CD3 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD3 chains play a major role in signaling through the TCR since they possess the ITAM motif in their cytoplasmic domain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/37\">",
"     37",
"    </a>",
"    ]. CD3 deficiency, which appears to have an autosomal recessive pattern of inheritance, has been reported in several patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CD3 delta, CD3 epsilon, or CD3 zeta deficiencies typically have a severe combined immunodeficiency phenotype (SCID), including the absence of T cells and normal, but non-functional B cells (due to the lack of T cell help). Patients with CD3 gamma deficiency have varying phenotypes, with some having SCID-like symptoms and some having a benign course [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/37-50\">",
"     37-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variations in clinical phenotype are based in part on the severity of the genotypic abnormality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD3 gamma deficiency &mdash; One patient with CD3 gamma deficiency had features of combined immunodeficiency, including failure to thrive, intractable diarrhea, and recurrent lung infections starting at age 11 months. This boy also had celiac disease and autoimmune hemolytic anemia. He died at 32 months of age from viral pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/46\">",
"       46",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A second patient, the brother of the previous child, had the same molecular defect (compound heterozygote for two different point mutations). Unlike his brother, he had infrequent minor infections and was still alive at age 10 years. However, he did develop autoimmune dilated cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. This difference in clinical phenotype is at the heart of a debate on the limitations of identifying gene defects in the diagnosis of primary immunodeficiencies. Gene mutation analysis needs to be used in combination with biomarkers for diagnosis and may be useful for genetic counseling and determining prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/51\">",
"       51",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A third patient, unrelated to the above two individuals, presented at six months of age with upper respiratory tract infections and urinary tract infections. At the age of two years, he spontaneously recovered from chickenpox. At last report, he was free of infection on intravenous immune globulin (IGIV) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/52\">",
"       52",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In another report, two patients with SCID due to CD3 gamma deficiency have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CD3 epsilon deficiency &mdash; CD3 epsilon deficiency typically results in T-B+NK+ SCID. In a consanguineous family, three offspring with CD3 epsilon deficiency had SCID in association with the complete absence of T cells. The first child died from pneumonitis at five months of age. The second child died at three months of age due to disseminated CMV. The third child died from disseminated adenovirus infection after receiving a haploidentical bone marrow transplantation from the father [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/48\">",
"       48",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      By comparison, one child presented with recurrent Haemophilus influenzae pneumonia and otitis media at two years of age. He had no evidence of autoimmune disease. At last report, he was receiving treatment with IGIV and prophylactic antibiotics and was doing well with no major infections [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/53\">",
"       53",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The difference between the individuals with severe disease and the relatively well child lies in the degree of CD3 epsilon deficiency. The mutation in those with severe immunodeficiency, a premature stop codon, resulted in the absence of CD3 epsilon. By comparison, the mutation in the relatively-well child did not totally prevent CD3 epsilon expression.",
"     </li>",
"     <li>",
"      CD3 delta deficiency &mdash; CD3 delta deficiency causes T-B+NK+ SCID. Patients presented at two to three months of age with severe life threatening viral infection and immunodeficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/50,53,54\">",
"       50,53,54",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In one report of three cousins, two died at two to three months of age from multi-organ failure. The third, who was identified at birth, underwent successful bone marrow transplantation and was alive and well at three years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/53,55\">",
"       53,55",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a second report of two siblings, the first child presented with CMV pneumonitis and oral candidiasis (thrush). She died from generalized cytomegalovirus infection at three months of age after hematopoietic cell transplantation for SCID. Her brother, diagnosed at birth, was well after cord blood stem cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/50,54\">",
"       50,54",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Two unrelated patients were identified with a leaky mutation in CD3 delta affecting T alpha beta but not T gamma delta cells [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/56\">",
"       56",
"      </a>",
"      ]. These patients presented at 5 and 13 months of age with failure to thrive, diarrhea, and respiratory disease. The younger patient died of multiorgan failure after transplantation, but the older patient was successfully transplanted and was alive and well at four years of age.",
"     </li>",
"     <li>",
"      CD3 zeta deficiency &mdash; Complete deficiency of CD3 zeta was reported in two patients who presented with T-B+NK+ SCID [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. One of these patients was successfully transplanted. Partial correction of the immunologic phenotype was observed in another patient with CD3 zeta deficiency as the result of somatic reversion [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/57\">",
"       57",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Partial deficiency of CD3 zeta chain expression was reported in a single family. An older sibling was hospitalized at 15 and 17 months of age for bronchitis and was diagnosed with asthma. The younger sibling presented at 11 months of age with recurrent bacterial and viral infections, chronic diarrhea, and failure to thrive. Small bowel biopsy results were characteristic of celiac disease, but the patient did not respond to a gluten-free diet. He died at three years of age after developing severe autoimmune hemolytic anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/38,57,59\">",
"       38,57,59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Laboratory features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major laboratory finding is the apparent absence of T cells by flow cytometry, as T cells are usually enumerated by anti-CD3 epsilon antibodies. Patients with CD3 gamma chain mutations also appear to have decreased expression of CD3 epsilon chain. Most patients with CD3 chain deficiency have at least some CD4+ or CD8+ cells in the periphery, the exception being some patients with CD3 delta deficiency, who tend to have a minimal number of T cells. CD3 zeta deficiency results in detectable, but decreased numbers of T cells. The presence of CD4+ or CD8+ cells without CD3+ cells suggests mutations in CD3.",
"   </p>",
"   <p>",
"    Thus, laboratory findings generally include (",
"    <a class=\"graphic graphic_table graphicRef76313 \" href=\"UTD.htm?36/35/37435\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absence of CD3+ cells",
"     </li>",
"     <li>",
"      Low numbers or absence of CD2+, CD4+, and CD8+ cells",
"     </li>",
"     <li>",
"      Decreased expression of TCR alpha-beta on PBMCs",
"     </li>",
"     <li>",
"      Normal numbers of B and NK cells",
"     </li>",
"     <li>",
"      Variable antibody response to protein antigens (absent to normal depending upon the defect) and a low response to polysaccharide antigens",
"     </li>",
"     <li>",
"      Low in-vitro T cell response to mitogens (eg, PHA) and anti-CD3",
"     </li>",
"     <li>",
"      Low (among those with CD3 gamma, delta, or zeta deficiencies) or normal (among those with CD3 epsilon deficiency) in vitro response to tetanus antigen and alloantigens",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Diagnosis and differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis is made via flow cytometry, examining TCR, CD3, CD4, and CD8 expression on the cell surface. If the sum of CD4+ and CD8+ cells is more than the reported number of T cells, CD3 and TCR expression must be examined. It is also imperative to evaluate the intensity of CD3 expression, since patients with CD3 gamma deficiency may have an adequate number of CD3 epsilon on the surface of their T cells, but in a decreased intensity of expression.",
"   </p>",
"   <p>",
"    The differential diagnosis includes the other causes for SCID that result in absent T cells in the periphery (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive therapy with antibiotics and immune globulin replacement therapy can be successful. Curative therapy requires hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/57,60-62\">",
"     57,60-62",
"    </a>",
"    ]. Gene therapy has not yet been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     p56lck deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several patients have been reported with deficiency of lymphocyte-specific protein-tyrosine kinase (Lck or p56lck), one of the protein tyrosine kinases that is activated upon engagement of the",
"    <span class=\"nowrap\">",
"     TCR/CD3",
"    </span>",
"    complex [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One patient with decreased expression of p56lck and an alternatively spliced transcript lacking the exon 7 kinase-encoding domain was reported. This infant presented with a SCID phenotype, CD4 lymphopenia, and absent CD28 expression on CD8+ T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another patient, with an aberrantly spliced Lck transcript lacking the entire exon 7, presented with common variable immunodeficiency and CD4 lymphopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decreased, but not absent or alternatively spliced, Lck was also reported in one patient with idiopathic CD4 lymphopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A homozygous missense mutation of the LCK gene leading to weak expression and absent kinase activity was reported in another patient [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A heterozygous dominant-negative missense mutation of the signaling adaptor protein Uncoordinated 119 (Unc119) was reported in one patient. This mutation resulted in disrupted lck function (impairment in localization and enzymatic activation) and CD4 lymphopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first reported patient with p56lck deficiency presented at age two months with failure to thrive, oral candidiasis, sepsis, diarrhea, and hypogammaglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/63\">",
"     63",
"    </a>",
"    ]. Enterobacter cloacae, rotavirus, and cytomegalovirus (CMV) were isolated. His course was dominated by persistent CMV infections, failure to thrive, and dependence upon",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    . The patient failed a trial of interleukin-2, and died soon after a bone marrow transplant was performed. Another patient had combined immunodeficiency, with chronic diarrhea, failure to thrive, recurrent sinopulmonary infections, and",
"    <span class=\"nowrap\">",
"     inflammatory/autoimmune",
"    </span>",
"    manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The second reported patient with Lck deficiency presented with a picture of common variable immunodeficiency associated with CD4 lymphopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/65\">",
"     65",
"    </a>",
"    ]. Other patients with milder genotypic abnormalities have autoimmune disease (eg, type 1 diabetes mellitus), but no evidence of immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28329/abstract/66\">",
"     66",
"    </a>",
"    ]. The patient with Unc119 mutation presented at age 32 years with recurrent",
"    <span class=\"nowrap\">",
"     sinusitis/otitis",
"    </span>",
"    media, frequent episodes of herpes zoster, widespread fungal nail infection, fungal dermatitis, and bronchiolitis obliterans organizing pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Laboratory diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory findings in p56lck deficiency include (",
"    <a class=\"graphic graphic_table graphicRef76313 \" href=\"UTD.htm?36/35/37435\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CD4 lymphopenia",
"     </li>",
"     <li>",
"      Hypogammaglobulinemia",
"     </li>",
"     <li>",
"      Normal NK cell number and function",
"     </li>",
"     <li>",
"      Progressive decline in the proliferative response to mitogens, IL-2, and anti-CD3 stimulation",
"     </li>",
"     <li>",
"      An intact response to alloantigens",
"     </li>",
"     <li>",
"      Decreased CD28 expression on CD8 cells",
"     </li>",
"     <li>",
"      Normal CD28 expression on CD4 cells",
"     </li>",
"     <li>",
"      Lack of upregulation of CD69 upon stimulation with anti-CD3",
"     </li>",
"     <li>",
"      Normal CD69 upregulation upon stimulation with PMA and ionomycin",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Diagnosis and differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is suggested by flow cytometry analysis of CD4+ cells, showing lymphopenia. However, definitive diagnosis requires the examination of p56lck splicing by reverse transcriptase-polymerase chain reaction (RT-PCR). Differential diagnosis includes other causes of combined immunodeficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is supportive with the administration of antibiotics and intravenous immune globulin. Bone marrow transplantation attempted in two patients was unsuccessful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     ZAP-70 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;ZAP-70 deficiency is a rare autosomal recessive form of combined immunodeficiency characterized by the selective absence of circulating CD8+ T cells and by abundant CD4+ T cells in the peripheral blood. The T cell abnormalities appear to be identical in most of the reported patients. This disorder is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42022?source=see_link\">",
"     \"ZAP-70 deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The T cell receptor (TCR) complex includes a number of components and associated molecules. The TCR is a heterodimer, either an alpha and a beta chain or a gamma and a delta chain, that binds to peptide presented on major histocompatibility complex (MHC) class I or II molecules by antigen presenting cells. CD4 and CD8 act as accessory molecules. TCR chains are also linked to CD3, which is important in transducing the signal that initiates a T cell activation and differentiation pathway. A number of downstream signaling molecules are involved in this pathway. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of T cell receptor biology'",
"      </a>",
"      above.) and (",
"      <a class=\"graphic graphic_figure graphicRef75287 \" href=\"UTD.htm?29/60/30670\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef76821 \" href=\"UTD.htm?9/9/9363\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef53512 \" href=\"UTD.htm?37/38/38499\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef63541 \" href=\"UTD.htm?6/23/6527\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef79731 \" href=\"UTD.htm?35/48/36611\">",
"       figure 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef76102 \" href=\"UTD.htm?21/33/22047\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Defects in the TCR complex or associated molecules can result in major T cell deficiency or dysfunction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Types of deficiencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with MHC class I deficiency (Bare lymphocyte syndrome type I) have been found to have defects in TAP1 or TAP2. The inheritance pattern is unclear due to its rarity. The clinical presentation is highly variable, depending upon the amount of MHC class I expression. Treatment is directed at infection control (antibiotics and immune globulin replacement therapy). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'MHC (HLA) class I deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MHC class II deficiency (Bare lymphocyte syndrome type II) is an autosomal recessive disease. The exact molecular defects are unknown. The clinical picture is one of severe combined immunodeficiency. Treatment is directed at infection control (antibiotics and immune globulin replacement therapy). Hematopoietic cell transplantation can be curative, but experience is limited. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'MHC (HLA) class II deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CD3 deficiency results from defects in one of the four CD3 chains (gamma, epsilon, delta, or zeta). It appears to have an autosomal recessive pattern of inheritance. The clinical features are highly variable, depending upon the affected chain and mutation. Treatment is directed at infection control (antibiotics and immune globulin replacement therapy). Hematopoietic cell transplantation can be curative, but experience is limited. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'CD3 deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deficiency of Lck (p56lck), one of the protein tyrosine kinases that is activated upon engagement of the",
"      <span class=\"nowrap\">",
"       TCR/CD3",
"      </span>",
"      complex, has been reported in several patients. Clinical presentation is variable, depending upon the severity of the mutation. Treatment is directed at infection control (antibiotics and immune globulin replacement therapy). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'p56lck deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       RAG1/RAG2",
"      </span>",
"      deficiency and ZAP-70 deficiency are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link\">",
"       \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42022?source=see_link\">",
"       \"ZAP-70 deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/1\">",
"      Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006; 24:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/2\">",
"      Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature 1999; 402:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/3\">",
"      Lanzavecchia A, Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 2000; 290:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/4\">",
"      Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/5\">",
"      Morgan NV, Goddard S, Cardno TS, et al. Mutation in the TCR&alpha; subunit constant gene (TRAC) leads to a human immunodeficiency disorder characterized by a lack of TCR&alpha;&beta;+ T cells. J Clin Invest 2011; 121:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/6\">",
"      Donato L, de la Salle H, Hanau D, et al. Association of HLA class I antigen deficiency related to a TAP2 gene mutation with familial bronchiectasis. J Pediatr 1995; 127:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/7\">",
"      de la Salle H, Hanau D, Fricker D, et al. Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science 1994; 265:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/8\">",
"      Teisserenc H, Schmitt W, Blake N, et al. A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. Immunol Lett 1997; 57:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/9\">",
"      Moins-Teisserenc HT, Gadola SD, Cella M, et al. Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet 1999; 354:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/10\">",
"      Maeda H, Hirata R, Chen RF, et al. Defective expression of HLA class I antigens: a case of the bare lymphocyte without immunodeficiency. Immunogenetics 1985; 21:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/11\">",
"      Schuurman RK, van Rood JJ, Vossen JM, et al. Failure of lymphocyte-membrane HLA-A and -B expression in two siblings with combined immunodeficiency. Clin Immunol Immunopathol 1979; 14:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/12\">",
"      Gadola SD, Moins-Teisserenc HT, Trowsdale J, et al. TAP deficiency syndrome. Clin Exp Immunol 2000; 121:173.",
"     </a>",
"    </li>",
"    <li>",
"     De la Salle H, Donato L, Zimmer J. HLA class I deficiencies. In: Primary immunodeficiency diseases: A molecular and genetic approach, 2nd ed, Ochs HD, Smith CIE, Puck JM (Eds), Oxford University Press, New York, NY 2007. p.242.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/14\">",
"      Raghavan M. Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome. J Clin Invest 1999; 103:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/15\">",
"      Cerundolo V, de la Salle H. Description of HLA class I- and CD8-deficient patients: Insights into the function of cytotoxic T lymphocytes and NK cells in host defense. Semin Immunol 2006; 18:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/16\">",
"      Zimmer J, Andr&egrave;s E, Donato L, et al. Clinical and immunological aspects of HLA class I deficiency. QJM 2005; 98:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/17\">",
"      Caversaccio M, Bon&eacute;l HM, Carter R, et al. TAP deficiency syndrome: chronic rhinosinusitis and conductive hearing loss. Eur Arch Otorhinolaryngol 2008; 265:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/18\">",
"      Villa-Forte A, de la Salle H, Fricker D, et al. HLA class I deficiency syndrome mimicking Wegener's granulomatosis. Arthritis Rheum 2008; 58:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/19\">",
"      Zimmer J, Donato L, Hanau D, et al. Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J Exp Med 1998; 187:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/20\">",
"      Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 2001; 19:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/21\">",
"      Villard J, Masternak K, Lisowska-Grospierre B, et al. MHC class II deficiency: a disease of gene regulation. Medicine (Baltimore) 2001; 80:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/22\">",
"      Masternak K, Muhlethaler-Mottet A, Villard J, et al. Molecular genetics of the Bare lymphocyte syndrome. Rev Immunogenet 2000; 2:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/23\">",
"      Elhasid R, Etzioni A. Major histocompatibility complex class II deficiency: a clinical review. Blood Rev 1996; 10:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/24\">",
"      Masternak K, Barras E, Zufferey M, et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 1998; 20:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/25\">",
"      van Eggermond MC, Tezcan I, Heemskerk MH, van den Elsen PJ. Transcriptional silencing of RFXAP in MHC class II-deficiency. Mol Immunol 2008; 45:2920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/26\">",
"      Durand B, Sperisen P, Emery P, et al. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J 1997; 16:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/27\">",
"      Villard J, Lisowska-Grospierre B, van den Elsen P, et al. Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency. N Engl J Med 1997; 337:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/28\">",
"      Nekrep N, Jabrane-Ferrat N, Wolf HM, et al. Mutation in a winged-helix DNA-binding motif causes atypical bare lymphocyte syndrome. Nat Immunol 2002; 3:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/29\">",
"      Steimle V, Durand B, Barras E, et al. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte sydrome). Genes &amp; Development 1995; 9:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/30\">",
"      Prod'homme T, Dekel B, Barbieri G, et al. Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course. Immunogenetics 2003; 55:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/31\">",
"      Wiszniewski W, Fondaneche MC, Le Deist F, et al. Mutation in the class II trans-activator leading to a mild immunodeficiency. J Immunol 2001; 167:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/32\">",
"      Klein C, Lisowska-Grospierre B, LeDeist F, et al. Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome. J Pediatr 1993; 123:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/33\">",
"      Saleem MA, Arkwright PD, Davies EG, et al. Clinical course of patients with major histocompatibility complex class II deficiency. Arch Dis Child 2000; 83:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/34\">",
"      Parvaneh N, Shahmahmoudi S, Tabatabai H, et al. Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency. J Clin Virol 2007; 39:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/35\">",
"      Picard C, Fischer A. Hematopoietic stem cell transplantation and other management strategies for MHC class II deficiency. Immunol Allergy Clin North Am 2010; 30:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/36\">",
"      Klein C, Cavazzana-Calvo M, Le Deist F, et al. Bone marrow transplantation in major histocompatibility complex class II deficiency: a single-center study of 19 patients. Blood 1995; 85:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/37\">",
"      Recio MJ, Moreno-Pelayo MA, Kili&ccedil; SS, et al. Differential biological role of CD3 chains revealed by human immunodeficiencies. J Immunol 2007; 178:2556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/38\">",
"      Alarcon B, Regueiro JR, Arnaiz-Villena A, Terhorst C. Familial defect in the surface expression of the T-cell receptor-CD3 complex. N Engl J Med 1988; 319:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/39\">",
"      Arnaiz-Villena A, Perez-Aciego P, Ballestin C, et al. Biochemical basis of a novel T lymphocyte receptor immunodeficiency by immunohistochemistry. A possible CD3 gamma abnormality. Lab Invest 1991; 64:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/40\">",
"      Arnaiz-Villena A, Timon M, Corell A, et al. Brief report: primary immunodeficiency caused by mutations in the gene encoding the CD3-gamma subunit of the T-lymphocyte receptor. N Engl J Med 1992; 327:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/41\">",
"      Arnaiz-Villena A, Timon M, Rodriguez-Gallego C, et al. T lymphocyte signalling defects and immunodeficiency due to the lack of CD3 gamma. Immunodeficiency 1993; 4:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/42\">",
"      Dave VP, Cao Z, Browne C, et al. CD3 delta deficiency arrests development of the alpha beta but not the gamma delta T cell lineage. EMBO J 1997; 16:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/43\">",
"      Le Deist F, Thoenes G, Corado J, et al. Immunodeficiency with low expression of the T cell receptor/CD3 complex. Effect on T lymphocyte activation. Eur J Immunol 1991; 21:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/44\">",
"      Haks MC, Krimpenfort P, Borst J, Kruisbeek AM. The CD3gamma chain is essential for development of both the TCRalphabeta and TCRgammadelta lineages. EMBO J 1998; 17:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/45\">",
"      Letourneur F, Klausner RD. Activation of T cells by a tyrosine kinase activation domain in the cytoplasmic tail of CD3 epsilon. Science 1992; 255:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/46\">",
"      Regueiro JR, Arnaiz-Villena A, Ortiz de Land&aacute;zuri M, et al. Familial defect of CD3 (T3) expression by T cells associated with rare gut epithelial cell autoantibodies. Lancet 1986; 1:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/47\">",
"      Regueiro JR, Perez-Aeiego P, Aparicio P, et al. Low IgG2 and polysaccharide response in a T cell receptor expression defect. Eur J Immunol 1990; 20:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/48\">",
"      Soudais C, de Villartay JP, Le Deist F, et al. Independent mutations of the human CD3-epsilon gene resulting in a T cell receptor/CD3 complex immunodeficiency. Nat Genet 1993; 3:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/49\">",
"      Zapata DA, Pacheco-Castro A, Torres PS, et al. CD3 immunodeficiencies. Immunol Allergy Clin North Am 2000; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/50\">",
"      Roifman CM. CD3 delta immunodeficiency. Curr Opin Allergy Clin Immunol 2004; 4:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/51\">",
"      Notarangelo LD, Sorensen R. Is it necessary to identify molecular defects in primary immunodeficiency disease? J Allergy Clin Immunol 2008; 122:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/52\">",
"      van Tol MJ, Sanal O, Yel L, et al. CD3gamma chain deficiency leading to a cellular immunodeficiency with mild clinical presentation. The Immunologist 1997; 1:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/53\">",
"      de Saint Basile G, Geissmann F, Flori E, et al. Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3. J Clin Invest 2004; 114:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/54\">",
"      Takada H, Nomura A, Roifman CM, Hara T. Severe combined immunodeficiency caused by a splicing abnormality of the CD3delta gene. Eur J Pediatr 2005; 164:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/55\">",
"      Dadi HK, Simon AJ, Roifman CM. Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency. N Engl J Med 2003; 349:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/56\">",
"      Gil J, Busto EM, Garcill&aacute;n B, et al. A leaky mutation in CD3D differentially affects &alpha;&beta; and &gamma;&delta; T cells and leads to a T&alpha;&beta;-T&gamma;&delta;+B+NK+ human SCID. J Clin Invest 2011; 121:3872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/57\">",
"      Rieux-Laucat F, Hivroz C, Lim A, et al. Inherited and somatic CD3zeta mutations in a patient with T-cell deficiency. N Engl J Med 2006; 354:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/58\">",
"      Roberts JL, Lauritsen JP, Cooney M, et al. T-B+NK+ severe combined immunodeficiency caused by complete deficiency of the CD3zeta subunit of the T-cell antigen receptor complex. Blood 2007; 109:3198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/59\">",
"      Fischer A, de Saint Basile G, Le Deist F. CD3 deficiencies. Curr Opin Allergy Clin Immunol 2005; 5:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/60\">",
"      Roifman CM, Grunebaum E, Dalal I, Notarangelo L. Matched unrelated bone marrow transplant for severe combined immunodeficiency. Immunol Res 2007; 38:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/61\">",
"      Grunebaum E, Mazzolari E, Porta F, et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 2006; 295:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/62\">",
"      Marcus N, Takada H, Law J, et al. Hematopoietic stem cell transplantation for CD3&delta; deficiency. J Allergy Clin Immunol 2011; 128:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/63\">",
"      Goldman FD, Ballas ZK, Schutte BC, et al. Defective expression of p56lck in an infant with severe combined immunodeficiency. J Clin Invest 1998; 102:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/64\">",
"      Hubert P, Bergeron F, Ferreira V, et al. Defective p56Lck activity in T cells from an adult patient with idiopathic CD4+ lymphocytopenia. Int Immunol 2000; 12:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/65\">",
"      Sawabe T, Horiuchi T, Nakamura M, et al. Defect of lck in a patient with common variable immunodeficiency. Int J Mol Med 2001; 7:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/66\">",
"      Nervi S, Atlan-Gepner C, Kahn-Perles B, et al. Specific deficiency of p56lck expression in T lymphocytes from type 1 diabetic patients. J Immunol 2000; 165:5874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/67\">",
"      Hauck F, Randriamampita C, Martin E, et al. Primary T-cell immunodeficiency with immunodysregulation caused by autosomal recessive LCK deficiency. J Allergy Clin Immunol 2012; 130:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28329/abstract/68\">",
"      Gorska MM, Alam R. A mutation in the human Uncoordinated 119 gene impairs TCR signaling and is associated with CD4 lymphopenia. Blood 2012; 119:1399.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3956 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_42_28329=[""].join("\n");
var outline_f27_42_28329=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF T CELL RECEPTOR BIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPES OF DEFICIENCIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL IMMUNODEFICIENCY SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14761190\">",
"      TCR alpha subunit constant (TRAC) deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Defects of V(D)J recombination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MHC (HLA) class I deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Laboratory features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MHC (HLA) class II deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Laboratory features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Diagnosis and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CD3 deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Laboratory features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Diagnosis and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      p56lck deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Laboratory diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Diagnosis and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ZAP-70 deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3956\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3956|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/60/30670\" title=\"figure 1\">",
"      Structure T cell receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/9/9363\" title=\"figure 2\">",
"      MHC I antigen processing and presentation pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/38/38499\" title=\"figure 3\">",
"      HLA TCR complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/23/6527\" title=\"figure 4\">",
"      Antigen presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/48/36611\" title=\"figure 5\">",
"      Major pathways of T cell activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/33/22047\" title=\"figure 6\">",
"      Scheme thymic T cell development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3956|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/35/37435\" title=\"table 1\">",
"      PBL levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/50/4908\" title=\"table 2\">",
"      MHC class II deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=related_link\">",
"      Antigen presenting cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=related_link\">",
"      Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30009?source=related_link\">",
"      Idiopathic CD4+ lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/10?source=related_link\">",
"      Severe combined immunodeficiency (SCID): Specific defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=related_link\">",
"      T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=related_link\">",
"      T cell receptor genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/25001?source=related_link\">",
"      T cell receptor signaling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42022?source=related_link\">",
"      ZAP-70 deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_42_28330="Misoprostol as a single agent for medical termination of pregnancy";
var content_f27_42_28330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Misoprostol as a single agent for medical termination of pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/42/28330/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28330/contributors\">",
"     Wesley Clark, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28330/contributors\">",
"     Caitlin Shannon, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28330/contributors\">",
"     Beverly Winikoff, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/42/28330/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28330/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/42/28330/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/42/28330/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/42/28330/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical methods for induced abortion have emerged over the past two decades as safe, effective, and feasible alternatives to surgery. Nonsurgical alternatives expand a woman's treatment options and, in turn, the quality of care [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/1\">",
"     1",
"    </a>",
"    ]. Moreover, in some settings, surgical options are not available to women or are not medically feasible.",
"   </p>",
"   <p>",
"    In first trimester abortion, combined treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    &nbsp;appears to be more effective than misoprostol-alone regimens, and thus, are considered the gold standard for medical induction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. However, misoprostol-alone regimens may be the treatment of choice in settings in which mifepristone is not available or is too costly.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    is commonly used as a single agent for second trimester induced abortion in the United States and many other parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    in pregnancy termination. Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    and other medical and surgical approaches to pregnancy termination and use of misoprostol for fetal demise or labor induction are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=see_link\">",
"     \"Mifepristone for the medical termination of pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link\">",
"     \"Overview of pregnancy termination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2841?source=see_link\">",
"     \"Spontaneous abortion: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=see_link\">",
"     \"Incidence, etiology, and prevention of stillbirth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41993?source=see_link\">",
"     \"Techniques for ripening the unfavorable cervix prior to induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    is a synthetic E1 prostaglandin (PGE1) developed and approved originally for the prevention of gastric ulcers. Misoprostol is not approved by the United States Food and Drug Administration for uterine evacuation in pregnant women.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    administration in pregnancy induces cervical effacement and uterine contractions at all gestational ages, thereby facilitating uterine evacuation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/7\">",
"     7",
"    </a>",
"    ]. The potency of misoprostol's effect, however, varies with gestational age, as well as with route of administration, dose, dosing interval, and cumulative dose.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gestational age &mdash; The sensitivity of the uterus to prostaglandins increases with gestational age [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/7\">",
"       7",
"      </a>",
"      ]. For this reason, providers generally use decreasing amounts of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      with increasing gestational age.",
"     </li>",
"     <li>",
"      Route of administration &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       Misoprostol",
"      </a>",
"      can be administered by the following routes: vaginal, oral, sublingual, buccal, or rectal [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/8-13\">",
"       8-13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum level &mdash; The pharmacokinetic profile varies by route [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/8,9,12,13\">",
"       8,9,12,13",
"      </a>",
"      ]. Oral or sublingual administration leads to a rapid peak in serum level, which appears to decrease in one to three hours. Conversely, with vaginal or buccal dosing, serum levels peak later and remain elevated longer [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Uterine activity &mdash; Regular and sustained uterine activity is more likely following vaginal, sublingual, or buccal compared with oral administration [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Moist versus dry tablets &mdash; Moistening of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      tablets does not appear to increase clinical effectiveness [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/14-17\">",
"       14-17",
"      </a>",
"      ]. A randomized trial evaluated first trimester abortion using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      followed by wet versus dry misoprostol; no difference was found between the two groups [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Absolute contraindications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suspected or confirmed ectopic pregnancy",
"     </li>",
"     <li>",
"      Gestational trophoblastic disease",
"     </li>",
"     <li>",
"      High risk of uterine rupture (ie, second or third trimester inductions in women with more than one prior hysterotomy, a prior classical or T-shaped uterine incision, or extensive transfundal uterine surgery)",
"     </li>",
"     <li>",
"      Intrauterine device (IUD; must be removed before",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      is administered)",
"     </li>",
"     <li>",
"      Allergy to prostaglandins",
"     </li>",
"     <li>",
"      Contraindications to medical or surgical uterine evacuations (eg, hemodynamically unstable, coagulopathy) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link\">",
"       \"Overview of pregnancy termination\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Relative contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    -alone regimens should be used with caution in women who are at risk for complications of pregnancy termination (eg, coagulopathy). Precautions specific to misoprostol are considered here. A full discussion of abortion complications is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of pregnancy termination\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk factors for uterine rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine rupture is a risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    use at any time during pregnancy. While the risk is likely higher is women with a uterine scar, there are few reports of this complication (",
"    <a class=\"graphic graphic_table graphicRef58285 \" href=\"UTD.htm?3/17/3357\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/18\">",
"     18",
"    </a>",
"    ]. In a systematic review of available studies, the risk of rupture was 0.3 percent among women with a prior cesarean delivery who were undergoing second trimester misoprostol-induced abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/19\">",
"     19",
"    </a>",
"    ]. Advanced gestational age, high gravidity (&ge;3 pregnancies) or uterine anomalies may also increase risk of rupture.",
"   </p>",
"   <p>",
"    Uterine rupture has only been reported once in women undergoing first trimester ruptures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the second trimester, uterine rupture is rare, but has been reported more frequently than in the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/21-29\">",
"     21-29",
"    </a>",
"    ]. Case reports of uterine rupture in women undergoing second trimester abortion with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    include women with scarred [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/21-26\">",
"     21-26",
"    </a>",
"    ] and unscarred uteri [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scarred uterus &mdash; There are no high quality data regarding the risk of uterine rupture with use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      for first or second trimester pregnancy termination. Among five published case series of women with a prior cesarean section who were undergoing second trimester misoprostol abortion (n = 858), two cases of uterine rupture were reported [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/21,22,30-32\">",
"       21,22,30-32",
"      </a>",
"      ]; however, they were underpowered to detect this rare complication.",
"      <br/>",
"      <br/>",
"      According to observational data regarding obstetric labor induction, misoprostol induction is contraindicated in women with more than one hysterotomy, a prior classical or T-shaped uterine incision, or extensive transfundal uterine surgery. It has not been established whether these risks apply equally to patients undergoing first or second trimester induction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link&amp;anchor=H15065615#H15065615\">",
"       \"Choosing the route of delivery after cesarean birth\", section on 'Inappropriate candidates'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We counsel women that a uterine scar is not a contraindication for first trimester misoprostol induction, but that the risk may increase with increasing gestational age, particularly in the late second trimester. We counsel women about risk and monitor them for signs of rupture.",
"     </li>",
"     <li>",
"      Unscarred uterus &mdash; In reports of uterine rupture in women without previous uterine surgery, risk factors included grand multiparity [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/26,27\">",
"       26,27",
"      </a>",
"      ], gestational age greater than 23 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/25\">",
"       25",
"      </a>",
"      ], and use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      in addition to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/26\">",
"       26",
"      </a>",
"      ]. However, oxytocin can generally be used safely in combination with misoprostol [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/27\">",
"       27",
"      </a>",
"      ]. For pregnancies at 23 or more weeks, it is controversial whether it is necessary to decrease the misoprostol dose or increase dosing interval, though it may be prudent to do so [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    is excreted transiently and at low levels in human breast milk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/35\">",
"     35",
"    </a>",
"    ]. It appears that the levels rise and decline within three to five hours of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/7,35\">",
"     7,35",
"    </a>",
"    ]. It is reasonable to counsel women who receive misoprostol while breastfeeding to pump and discard all milk produced within five hours after each dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION AND PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All women should undergo an initial evaluation, including a medical history and a physical examination confirming gestational age. Ultrasound is necessary only if there is uncertainty about gestational age, pregnancy location or the presence of gestational trophoblastic disease. If an ultrasound is not performed, the pregnancy should be confirmed with a urine or serum human chorionic gonadotropin (hCG). Blood type and antibody status are checked and Rh immune globulin given if indicated. If a patient has an IUD, it must be removed.",
"   </p>",
"   <p>",
"    One of the advantages of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    induction is that it can be performed safely and effectively without mechanical dilation (eg, rigid or osmotic dilators). Some providers augment the procedure with pretreatment laminaria for inductions after 15 weeks. However, two randomized trials in women undergoing second trimester termination reported that use of laminaria compared with no mechanical dilation did not reduce (16 and 17 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/36\">",
"     36",
"    </a>",
"    ] and may prolong (11 versus 14 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/37\">",
"     37",
"    </a>",
"    ] induction time; one trial found an increase in the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    in patients treated with laminaria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/37\">",
"     37",
"    </a>",
"    ]. A full discussion of cervical preparation for pregnancy termination can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of pregnancy termination\", section on 'Cervical preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no high quality evidence regarding the use of antibiotic prophylaxis for medical abortion (ie, no invasive methods for cervical preparation or uterine evacuation). However, due to several deaths due to clostridial sepsis in the United States in patients who received vaginal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    , some organizations, such as Planned Parenthood (the largest abortion provider in the United States), have introduced the use of prophylactic antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. However, deaths due to clostridial infection have been reported among women administering misoprostol both vaginally and buccally [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=see_link\">",
"     \"Mifepristone for the medical termination of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pretreatment evaluation for pregnancy termination is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pregnancy termination\", section on 'Preoperative considerations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"     \"Prevention of Rh(D) alloimmunization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DATA ON DRUG ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    regimen at any gestational age is determined by achieving a balance among effectiveness, adverse effects, and acceptability to patients. As an example, higher doses and shorter dosing intervals increase effectiveness, but also may result in higher rates of adverse effects and complications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Route of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effectiveness (defined as complete abortion without surgical intervention) is higher with vaginal compared with oral administration in both first and second trimesters [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. However, in a randomized trial, women preferred oral rather than vaginal dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accumulating evidence regarding sublingual administration appears promising regarding effectiveness and patient acceptability [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Buccal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    is also used frequently in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    . As a single agent, two studies have found that buccal misoprostol can be effective for first trimester induction and may be effective in second trimester abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Its use has not been compared to either vaginal administration or sublingual administration, which are preferable [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral versus vaginal dosing &mdash; At 8 or less weeks of gestation, a comparative study evaluated three oral and four vaginal regimens in 260 women showed that the rate of complete abortion is higher with vaginal compared with oral administration (43 to 80 versus 39 to 50 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/41\">",
"       41",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      For pregnancies between 9 and 12 weeks, there are no high quality data comparing vaginal with oral administration. However, observational studies of vaginal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      use have reported consistently high rates of complete abortion (85 to 90 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/50-60\">",
"       50-60",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      At 13 or more weeks, randomized trials comparing vaginal with oral dosing found that the vaginal route was more effective (86 to 100 versus 45 to 89 percent) and had a shorter induction-to-delivery interval (10 to 15 hours versus 12 to 35 hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/6,43,44,61\">",
"       6,43,44,61",
"      </a>",
"      ]. Adverse effects were similar between the two routes, with the possible exception of a higher incidence of fever with vaginal dosing [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/43\">",
"       43",
"      </a>",
"      ], and of nausea and diarrhea with oral dosing [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/61\">",
"       61",
"      </a>",
"      ]. Findings on adverse effects are not consistent and thus do not provide high quality evidence for guiding route of administration.",
"     </li>",
"     <li>",
"      Sublingual versus vaginal dosing &mdash; In pregnancies at 12 weeks of gestation or less, data suggest that the sublingual route may be as effective as the vaginal route when dosed appropriately [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/41,45,62\">",
"       41,45,62",
"      </a>",
"      ]. In a randomized trial that compared two vaginal and two sublingual regimens in 2000 women, vaginal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      administered every 3 or 12 hours and sublingual misoprostol every three hours were similarly effective (83 to 85 percent), but sublingual misoprostol every 12 hours was less effective (78 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/62\">",
"       62",
"      </a>",
"      ]. Women preferred sublingual to vaginal administration. Side effects tended to be more common among women taking misoprostol at 3-hour compared to 12-hour intervals, vaginal or sublingual; and this finding was significant for incidence of fever. Diarrhea and chills were slightly more common in women taking misoprostol sublingually compared to vaginally, but this difference was not statistically significant and, regardless, may not be clinically relevant.",
"      <br/>",
"      <br/>",
"      Similarly, the sublingual route may be as effective as the vaginal route for termination after 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/47,61,63-67\">",
"       47,61,63-67",
"      </a>",
"      ]. One meta-analysis demonstrated that efficacy at 24 hours was similar (pooled RR 1.04, 95% CI 0.93-1.7), but that vaginal misoprostol may be more successful at 48 hours (pooled RR 0.96; 95% CI 0.93-0.99) and may shorten the induction-to-abortion interval (WMD -4.54, 95% CI -8.03 to -1.05) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/66\">",
"       66",
"      </a>",
"      ]. A second meta-analysis of 40 randomized trials examining medical methods of uterine evacuation for women 12 to 28 weeks pregnant found that while misoprostol was more frequently vaginally administered, sublingual administration was equally effective [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/67\">",
"       67",
"      </a>",
"      ]. Rates of adverse effects are similar between the two types of dosing; however, patients prefer the sublingual route [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/47,63,64\">",
"       47,63,64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Buccal versus oral or vaginal dosing &mdash; Buccal administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      as a single agent for medical termination of pregnancy in the first trimester appears promising [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]. Randomized trial data for administration of misoprostol in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      for pregnancy up to eight to nine weeks of gestation have found that the efficacy of buccal dosing is similar to vaginal and better than oral dosing [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]. Buccal administration was associated with a slight increase in nausea over either oral or vaginal dosing. Patient satisfaction was high across all routes. Used as a single agent, buccal misoprostol was found to have an efficacy of 76 percent among women less than 9 weeks pregnant (n = 147) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/48\">",
"       48",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Studies regarding buccal dosing in the second trimester have also yielded favorable results, but there are no studies regarding use of buccal misoprostol as a single agent for second trimester pregnancy termination [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/72,73\">",
"       72,73",
"      </a>",
"      ]. In one randomized trial, the initial misoprostol dose was administered vaginally, and subsequent doses were given either buccally or vaginally [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/74\">",
"       74",
"      </a>",
"      ]. The median time to abortion in the buccal group did not differ significantly in the buccal compared with vaginal dosing groups (15 versus 12 hours); no difference was found in patient preference for route of administration.",
"     </li>",
"     <li>",
"      Combined-route regimens for second trimester terminations &mdash; Regimens that combine an initial vaginal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      dose followed by oral doses have been commonly used for terminations after 12 weeks and appear to be as effective as vaginal-only regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/37,44,75-77\">",
"       37,44,75-77",
"      </a>",
"      ]. The rationale is to maximize effectiveness and acceptability, while minimizing induction-to-delivery interval, adverse effects and complications. In a randomized trial of 43 women at 13 to 23 weeks of gestation, an initial 800 mcg vaginal misoprostol dose was followed every eight hours by 400 mcg given either orally or vaginally; effectiveness (82 and 87 percent) and induction-to-delivery interval (16 and 21 hours) were similar between the oral and vaginal groups [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/77\">",
"       77",
"      </a>",
"      ]. A randomized trial demonstrated that 200 mcg buccal doses repeated at six-hour intervals, following an initial 400 mcg vaginal dose, result in a similar induction-to-delivery interval (15 versus 12 hours, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Dose and dosing interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal regimen is a dose and dosing interval balance which generate sufficient and sustained uterine activity while minimizing adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/78\">",
"     78",
"    </a>",
"    ]. Longer dosing intervals have the benefit of exposing a woman to a decreased risk of adverse effects. Conversely, shorter dosing intervals (closer to three hours) may be necessary to generate sufficient uterine activity, in particular if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    is given via a route with a rapid rise and fall in serum levels (ie, oral and sublingual) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/9\">",
"     9",
"    </a>",
"    ]. Uterine hyperstimulation is rare; however, the risk may increase with shorter dosing intervals.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      9 or less weeks &mdash; Vaginal administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      appears to be more effective at 800 mcg (generally 80 to 90 percent) than 200 or 400 mcg (23 to 46 percent), according to observational data [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/52\">",
"       52",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A vaginal dosing interval of 3 to 24 hours (800 mcg PV; total of three to five doses) is typically used to terminate pregnancies up to nine weeks, with reported success rates of 85 to 93 percent in non-comparative studies [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/78\">",
"       78",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There are no high quality data comparing different doses of sublingual misoprostol for terminations at &le;12 weeks. In studies of sublingual-dosing alone and comparative trials with vaginal dosing, 400 to 800 mcg SL is typically used [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/41,45,62\">",
"       41,45,62",
"      </a>",
"      ]. As noted above, 3- rather than 12-hour dosing interval was found to be significantly more effective in a randomized trial (84 versus 78 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      10 to 12 weeks &mdash; Lower success rates for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      -alone have been reported for pregnancies at 10 to 12 weeks of gestation (84 to 87 percent) in a few descriptive studies [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/52,58,59,79,80\">",
"       52,58,59,79,80",
"      </a>",
"      ]. The most effective regimen appears to be 800 mcg PV every 12 to 24 hours for a maximum of three doses [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/58,59\">",
"       58,59",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Data from a case series of 50 women suggest that sublingual administration is also effective; the regimen used was 600 mcg SL every three hours up to five doses [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      13 to 22 weeks &mdash; Two",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      regimens, 400 mcg PV every three hours OR 600 PV mcg every 12 hours were safe, effective, and resulted in low induction-to-delivery interval in randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/81-83\">",
"       81-83",
"      </a>",
"      ]. However, these two regimens have not been compared to each other.",
"      <br/>",
"      <br/>",
"      As noted above, it is unclear whether sublingual administration is more or less effective than vaginal in this gestational age range. More research is needed to determine whether sublingual administration should be used among women with gestations 13 to 22 weeks, and the appropriate regimen (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Route of administration'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      23 to 26 weeks &mdash; Many studies have examined the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      -alone regimens beyond 23 weeks of gestation, and data show that the method, employing a variety of regimens, can be safely and effectively used in women with advanced gestations [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/44,75,82-87\">",
"       44,75,82-87",
"      </a>",
"      ]. In general, however, termination after 23 weeks is not common in the United States, and an optimal regimen has not been established.",
"      <br/>",
"      <br/>",
"      As noted above, uterine sensitivity to prostaglandins and risk of uterine rupture increase with gestational age. Therefore, it may be prudent to use a decreased dose or increased dosing interval in this gestational age range [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/88\">",
"       88",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacokinetics'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Number of doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pregnancies at 12 or less weeks, it appears that there is little increase in effectiveness after the second dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/60,89\">",
"     60,89",
"    </a>",
"    ], although most studies have evaluated regimens of three to five doses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/78\">",
"     78",
"    </a>",
"    ]. As an example, in one study, effectiveness after a second or third dose were similar (86 and 88 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on second trimester medical terminations with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    show that multiple doses are highly effective compared to single doses. As noted above, recommended doses are lower than doses used for first trimester terminations since the uterine is more sensitive to misoprostol and the risk of rupture appears greater [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/66,67,90\">",
"     66,67,90",
"    </a>",
"    ]. As an example, 25 to 50 mcg doses are generally used for labor induction in the third trimester. The need for repeat doses should be evaluated prior to administration and based on lack of relevant clinical signs of progression (eg, insufficient uterine activity or cervical dilation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The regimens listed below are consistent with the regimens proposed by a meeting convened by the World Health Organization (WHO) as a prelude to WHO guidelines (",
"    <a class=\"graphic graphic_table graphicRef60845 \" href=\"UTD.htm?34/22/35181\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/78,88,91\">",
"     78,88,91",
"    </a>",
"    ]. All gestational ages refer to weeks of amenorrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     9 or less weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    may be administered either in a clinic or at home.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      800 mcg SL every three hours for up to three doses [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/62\">",
"       62",
"      </a>",
"      ] OR",
"     </li>",
"     <li>",
"      800 mcg PV every 3 to 12 hours for up to three doses [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/41,62\">",
"       41,62",
"      </a>",
"      ] OR",
"     </li>",
"     <li>",
"      800 mcg buccally every two to three hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     10 to 12 weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest administration in a clinic only due to increased risk of excessive bleeding and possibly of uterine rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      800 mcg PV every 3 to 12 hours for up to three doses [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     13 to 22 weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be administered only in a clinic setting with immediate access to emergency surgery and blood transfusion. If delivery has not occurred at 24 hours, the protocol may be repeated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      400 mcg PV every three to four hours (max five doses) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/81\">",
"       81",
"      </a>",
"      ] OR",
"     </li>",
"     <li>",
"      600 mcg PV every 12 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/82\">",
"       82",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     23 or more weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be administered only in a clinic setting with immediate access to emergency surgery and blood transfusion. As noted above, there is no well-established regimen for this gestational age range, however, it may be prudent to use a decreased dose (200 to 400 mcg) or increased dosing interval (six hours). One option is to give 400 mcg PV every six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H11\">",
"     'Dose and dosing interval'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MONITORING DURING TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women are monitored during treatment whether it occurs at home or in a clinic setting. The goals of monitoring are to assess treatment efficacy and assess for complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     At-home treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A woman undergoing medical termination at home should have easy access to a clinician who can answer questions and manage complications medically or surgically. Patient education should include how to recognize complications (eg, fever, abdominal pain, or prolonged or excessive bleeding) (",
"    <a class=\"graphic graphic_table graphicRef60845 \" href=\"UTD.htm?34/22/35181\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, a woman should also call her provider if it does not seem that the treatment has been effective. Typically, if 48 hours have passed since completion of treatment and a woman has not had bleeding greater than a menstrual period, it is likely that she may have an incomplete abortion or continuing pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     In-clinic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of presumed products of conception or pelvic examination are performed before each additional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    dose is administered in order to determine whether the fetus has been expelled. The frequency and strength of uterine contractions are also monitored, and additional doses should be deferred if uterine contractions are strong (strong to palpation or by patient report)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    too frequent (&gt;3",
"    <span class=\"nowrap\">",
"     contractions/10",
"    </span>",
"    min) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In pregnancies at 13 weeks or greater, if a woman does not abort after 24 hours, the option of a second course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    treatment or surgical evacuation can be offered [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/81,83\">",
"     81,83",
"    </a>",
"    ]. There are insufficient data on the safety and effectiveness of augmentation with other uterotonics (eg, prostaglandins or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/88\">",
"     88",
"    </a>",
"    ]. As with misoprostol, if additional uterotonics are used, precautions should be taken to avoid uterine hyperstimulation, as it may lead to rupture.",
"   </p>",
"   <p>",
"    Expulsion of the placenta should be confirmed. Expulsion usually occurs shortly after the fetus is delivered. After expulsion, the placenta should be examined to see whether it is complete.",
"   </p>",
"   <p>",
"    Advice regarding time interval to wait for placental expulsion varies from 30 minutes to four hours; in a retrospective study, there was no morbidity associated with a waiting period of four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/93\">",
"     93",
"    </a>",
"    ]. If two or more hours have passed and the placenta has not delivered, an infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    10 units in 500 mL of normal saline administered intravenously at a rate of 20 to 30 drops per minute may be given [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/88\">",
"     88",
"    </a>",
"    ]. If the placenta has not delivered after infusion of oxytocin or the woman starts bleeding excessively, manual or surgical removal of the placenta may be required.",
"   </p>",
"   <p>",
"    Before discharge from the clinic, clinicians should observe women for at least four hours to monitor vital signs and observe for severe abdominal pain or excessive vaginal bleeding.",
"   </p>",
"   <p>",
"    If 48 hours have passed and abortion is not complete, surgical evacuation is typically performed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After treatment, women should be educated about how to recognize complications (eg, fever, abdominal pain, or prolonged or excessive bleeding) (",
"    <a class=\"graphic graphic_table graphicRef60845 \" href=\"UTD.htm?34/22/35181\">",
"     table 2",
"    </a>",
"    ). A follow-up visit is conducted at one to two weeks post-treatment. A thorough clinical history and bimanual pelvic examination is performed to evaluate uterine size, bleeding, and assess for infection.",
"   </p>",
"   <p>",
"    The most important questions to ask at the follow-up visit are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Do you feel pregnant?",
"     </li>",
"     <li>",
"      Did you see the expulsion of the gestational sac or fetus?",
"     </li>",
"     <li>",
"      How much bleeding did you have?",
"     </li>",
"     <li>",
"      Are you still bleeding?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These questions and a pelvic examination to determine uterine size are sufficient to detect most women in need of further treatment for incomplete abortion (retained products of conception, no or inconsistent uterine growth, and lack of cardiac activity on ultrasound) or ongoing pregnancy (uterine growth consistent with the time elapsed between the first and follow-up visits and cardiac activity on vaginal ultrasound).",
"   </p>",
"   <p>",
"    If there is uncertainty about whether there is an incomplete abortion (retained products of conception, no or inconsistent uterine growth, and lack of cardiac activity on ultrasound) or ongoing pregnancy (uterine growth consistent with the time elapsed between the first and follow-up visits and cardiac activity on vaginal ultrasound), a vaginal ultrasound examination may be necessary. Generally speaking, a serum hCG is only used when there is concern about non-uterine pregnancy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when ultrasound is not available.",
"   </p>",
"   <p>",
"    While hCG concentration may remain elevated for weeks after complete abortion, a measurement that falls to less than 20 percent of its pre-procedure value generally indicates successful pregnancy termination [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/94\">",
"     94",
"    </a>",
"    ]. Also, there is no consensus regarding the upper limit of endometrial thickness associated with a successful medical abortion; therefore, it is not a good diagnostic tool for determining whether further intervention may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/95-99\">",
"     95-99",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=see_link\">",
"     \"Mifepristone for the medical termination of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contraceptive method can be started as soon as possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H35#H35\">",
"     \"Overview of pregnancy termination\", section on 'Contraception'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;In early pregnancy, some studies suggest that pregnancy termination efficacy may be higher among women at six weeks and less [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/100,101\">",
"     100,101",
"    </a>",
"    ] compared with those at six to eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. This trend toward higher effectiveness with decreasing gestational age is similar to the results seen in large trials of combined",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Effectiveness (defined as complete abortion) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    alone for pregnancy termination is as follows.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &le;9 weeks (weeks of amenorrhea): 75 to 85 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/62,78\">",
"       62,78",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      10 to 12 weeks: 80 to 85 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/78\">",
"       78",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      &ge;13 weeks: 80 to 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/88\">",
"       88",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    is a safe and well-tolerated medication [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/102\">",
"     102",
"    </a>",
"    ]. Gastrointestinal symptoms (nausea, diarrhea) and fever are the most common adverse effects of misoprostol. These are generally transient and self-limiting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Gastrointestinal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea is the major adverse reaction that has been reported consistently, but it is usually mild and self-limiting. Nausea and vomiting may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/102\">",
"     102",
"    </a>",
"    ]. The majority of cases can be managed expectantly or with anti-emetic or",
"    <span class=\"nowrap\">",
"     anti-/diarrheal",
"    </span>",
"    medication.",
"   </p>",
"   <p>",
"    These symptoms have been observed with all four routes of administration; severity may be dose and interval dependent (ie, higher doses and shorter dosing intervals may lead to increased symptoms) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/62,78,100,103\">",
"     62,78,100,103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever, even in the absence of infection is a common effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    , reported in 5 to 88 percent of patients undergoing first trimester abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/7,52,78\">",
"     7,52,78",
"    </a>",
"    ]. There is one case report of severe hyperthermia (41.9",
"    <span class=\"nowrap\">",
"     C/107.4",
"    </span>",
"    F) in a woman who received misoprostol for postpartum hemorrhage prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/104\">",
"     104",
"    </a>",
"    ]. Fever associated with misoprostol should subside within 24 hours, and antipyretics may be given as needed. If fever persists beyond 24 hours, a women should be evaluated for infection.",
"   </p>",
"   <p>",
"    Concern has emerged in North America following the reports of six cases of Clostridia-associated fatal toxic shock syndrome following use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    for early pregnancy termination (five cases associated with sordellii and one with perfringens) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/105-108\">",
"     105-108",
"    </a>",
"    ]. An additional case (of perfringens) was recently reported in a woman who used laminaria and misoprostol for second trimester termination. Although several hypotheses on the mechanism of infection have been put forth, no consensus has been reached [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/109-111\">",
"     109-111",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=see_link&amp;anchor=H18#H18\">",
"     \"Mifepristone for the medical termination of pregnancy\", section on 'Infection'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Prevention of adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretreatment with antipyretic and antidiarrheal medications may slightly reduce the severity of gastrointestinal adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/112\">",
"     112",
"    </a>",
"    ]. In a randomized trial of women undergoing pregnancy termination at &le;7 weeks, pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    4 mg of loperamide and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    500 mg prior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    800 mcg pv compared to no pretreatment led to a significant reduction in incidence of diarrhea (23 versus 44 percent), but no difference in vomiting or",
"    <span class=\"nowrap\">",
"     fever/chills.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications",
"    specific to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    -only pregnancy termination are discussed below. As with any uterine evacuation procedure, bleeding or infection may occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of pregnancy termination\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Incomplete abortion",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     First trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women undergoing first trimester inductions, management of ongoing pregnancy (cardiac activity on ultrasound) or incomplete abortion (sac or other evidence of products of conception, but no gestational growth and no cardiac activity on ultrasound) are generally different. We assess women at the follow-up visit (one to two weeks) and advise surgery for all ongoing pregnancies. For incomplete abortion, we advise expectant management or a second dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    . For women who receive a second dose, we schedule a second follow-up assessment at one to two weeks.",
"   </p>",
"   <p>",
"    We generally don't give more than one additional dose. This is because the cumulative benefit of additional doses is not established and requiring multiple follow-up visits increases the chance of loss-to-follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Second trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women in second trimester, management of retained products of conception (POCs) depends on the point in the process at which they are suspected or diagnosed.",
"   </p>",
"   <p>",
"    After fetal expulsion and before discharge from the hospital or clinic, clinicians should confirm that the fetus and placenta have been completely expelled.",
"   </p>",
"   <p>",
"    Many clinicians manage retained products of conception (POCs) with surgical evacuation. Clinicians can choose either dilatation and curettage or manual vacuum aspiration, depending on the clinical situation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4453?source=see_link\">",
"     \"Surgical termination of pregnancy: First trimester\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=see_link\">",
"     \"Termination of pregnancy: Second trimester\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some clinicians treat retained POCs after a second trimester induction with an additional dose or two of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    . The efficacy of this practice has not been established in the literature, but avoiding surgical intervention is always recommended, and there are no known dangers of giving additional misoprostol doses after fetal expulsion.",
"   </p>",
"   <p>",
"    It is rare for retained POCs to be detected only after discharge from the clinic, and there is no standard approach. Management (expectant management, additional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    , or surgery) should be tailored to the patient's preferences and the clinical situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Uterine rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    , and other agents which stimulate uterine contractions (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    , other prostaglandins), may increase risk of dehiscence or a prior uterine scar or uterine rupture. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Risk factors for uterine rupture'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Preprocedure screening of patients for risk factors and close observation during treatment are crucial to prevent or detect early signs of uterine rupture. In addition, the minimum cumulative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    dose should be used (ie, lowest dose, longest dosing interval, lowest number or total doses).",
"   </p>",
"   <p>",
"    Clinical manifestations of uterine rupture following medical termination of pregnancy are variable. In women with known uterine scarring, uterine rupture should always be strongly considered if severe and persistent abdominal pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs of intraabdominal hemorrhage are present. Vaginal bleeding is not a cardinal symptom, as it may be modest, despite major intraabdominal hemorrhage. Other clinical manifestations include hypotension ranging from subtle to severe (hypovolemic shock), cessation of uterine contractions, and uterine tenderness. Hematuria may occur if the rupture extends to the bladder. In a stable patient, ultrasound examination may confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/23,113\">",
"     23,113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link&amp;anchor=H15065615#H15065615\">",
"     \"Choosing the route of delivery after cesarean birth\", section on 'Inappropriate candidates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rupture or dehiscence is managed with exploratory laparotomy, with either uterine repair or hysterectomy. Conservative surgery also requires completion of the pregnancy termination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Questions regarding the teratogenicity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    may arise in cases where complete abortion is not achieved after one or more doses and a woman does not follow-up or chooses to continue a pregnancy. The teratogenic risk of misoprostol appears to be low and generally limited to first trimester exposure, according to a review of case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/114\">",
"     114",
"    </a>",
"    ]. Despite the low risk, women who do not abort after induction with misoprostol should be counseled about the risk of fetal malformation.",
"   </p>",
"   <p>",
"    The mechanism for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    -associated fetal malformations appears to be vascular disruption, possibly due to alteration of fetal blood flow due to uterine contractions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/88,114-117\">",
"     88,114-117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     MISOPROSTOL-ALONE COMPARED TO OTHER REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Misoprostol versus other prostaglandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with other prostaglandins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    has less adverse effects, is orally active, temperature stable, less expensive, and widely available, including: PGE2 (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/38/13927?source=see_link\">",
"     dinoprostone",
"    </a>",
"    ) and PGF2alpha (carboprost) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review of randomized trials in women undergoing pregnancy termination in the second or third trimester, vaginal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    compared with gemeprost (another PGE1) was associated with reduced narcotic analgesia (RR 0.64, 95% CI 0.49&ndash;0.84) and surgical evacuation of the uterus (RR 0.71, 95% CI 0.53&ndash;0.95) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Misoprostol versus mifepristone/misoprostol",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combined regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    is more effective than misoprostol-alone in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/89\">",
"     89",
"    </a>",
"    ]; the misoprostol-only regimen would be of use in those settings where mifepristone is not available.",
"   </p>",
"   <p>",
"    In addition, compared with combined therapy, women who administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    -alone may experience more fever and chills (probably due to higher and repeated doses), whereas women administered the combined therapy may experience more nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/101\">",
"     101",
"    </a>",
"    ]. Pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    may also reduce the pain associated with the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Misoprostol versus methotrexate/misoprostol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choice of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    -alone and combined",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"      methotrexate",
"     </a>",
"     /misoprostol",
"    </span>",
"    is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Data from randomized trials regarding the comparative efficacy of the two regimens are variable. Data from a large retrospective series reported that use of methotrexate with misoprostol was more effective than misoprostol-alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/42/28330/abstract/2\">",
"     2",
"    </a>",
"    ]. However, methotrexate is not widely available and is more cumbersome to use than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    and misoprostol and misoprostol alone. Also, it can only be used safely through seven weeks of gestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/47/42739?source=see_link\">",
"       \"Patient information: Abortion (pregnancy termination) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Pretreatment considerations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women seeking pregnancy termination at nine or less weeks of gestation, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      versus misoprostol alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). However, in settings where other medications are not accessible, use of misoprostol-alone for early pregnancy termination is an appropriate and effective choice. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Misoprostol-alone compared to other regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       Misoprostol",
"      </a>",
"      is commonly used as a single agent for second trimester induced abortion in the United States and many other parts of the world. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women undergoing pregnancy termination at 14 or more weeks, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      over gemeprost (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Misoprostol versus other prostaglandins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women undergoing second trimester pregnancy termination who are at high risk of uterine rupture (more than one hysterotomy, a prior classical or T-shaped uterine incision, or extensive transfundal uterine surgery [eg, myomectomy]), we suggest against using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Misoprostol induction for pregnancy termination appears to be safe in women with one prior low transverse hysterotomy. Rupture is rarely associated with misoprostol use in first trimester. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors for uterine rupture'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link&amp;anchor=H15065615#H15065615\">",
"       \"Choosing the route of delivery after cesarean birth\", section on 'Inappropriate candidates'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Clinical protocol",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women undergoing pregnancy termination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      -alone, we suggest sublingual, rather than vaginal or oral, misoprostol dosing (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Buccal dosing may be a reasonable alternative to sublingual. Sublingual and vaginal administration appear to be comparable in effectiveness and safety in randomized trials. Vaginal administration is more effective than oral, however, equivalent safety has not been confirmed. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Route of administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women at nine or less weeks,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      can be administered at home or in a clinic setting. At 10 or more weeks, we conduct misoprostol treatment and monitoring in a clinic. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The potency of the effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      varies with gestational age, as well as with route of administration, dose, dosing interval, and cumulative dose. Clinical protocols vary by gestational age. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Data on drug administration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical regimen'",
"      </a>",
"      above.)&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef60845 \" href=\"UTD.htm?34/22/35181\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms (nausea, vomiting, diarrhea) and fever are the most common adverse effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      . These are generally transient and self-limiting. It is reasonable to give prophylactic anti-diarrheal medication to decrease the incidence of diarrhea; pretreatment does not appear to decrease other side effects. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Posttreatment issues",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women should be educated about how to recognize complications (eg, fever, abdominal pain, or prolonged or excessive bleeding). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Incomplete abortion or continuing pregnancy are the most common complications of medical abortion. This can be managed expectantly, medically, or surgically. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uterine rupture should be suspected in a woman with severe or persistent abdominal pain and signs of intraabdominal bleeding. Prompt laparotomy is indicated in patients with a presumptive diagnosis of uterine rupture. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/1\">",
"      Borgatta L, Mullally B, Vragovic O, et al. Misoprostol as the primary agent for medical abortion in a low-income urban setting. Contraception 2004; 70:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/2\">",
"      Aldrich T, Winikoff B. Does methotrexate confer a significant advantage over misoprostol alone for early medical abortion? A retrospective analysis of 8678 abortions. BJOG 2007; 114:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/3\">",
"      Wiebe ER, Trouton KJ, Lima R. Misoprostol alone vs. methotrexate followed by misoprostol for early abortion. Int J Gynaecol Obstet 2006; 95:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/4\">",
"      Ozeren M, Bilekli C, Aydemir V, Bozkaya H. Methotrexate and misoprostol used alone or in combination for early abortion. Contraception 1999; 59:389.",
"     </a>",
"    </li>",
"    <li>",
"     United Nations Development Program/United Nations Fund for Population Activities/World Health Organization/World Bank Special Program of Research Development and Research Training in Human Reprod. Annual Technical Report, 1997. World Health Organization, Geneva, Switzerland 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/6\">",
"      Saha S, Bal R, Ghosh S, Krishnamurthy P. Medical abortion in late second trimester--a comparative study with misoprostol through vaginal versus oral followed by vaginal route. J Indian Med Assoc 2006; 104:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/7\">",
"      Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 2007; 99 Suppl 2:S160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/8\">",
"      Zieman M, Fong SK, Benowitz NL, et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol 1997; 90:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/9\">",
"      Tang OS, Schweer H, Seyberth HW, et al. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod 2002; 17:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/10\">",
"      Danielsson KG, Marions L, Rodriguez A, et al. Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet Gynecol 1999; 93:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/11\">",
"      Arvidsson C, Hellborg M, Gemzell-Danielsson K. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. Eur J Obstet Gynecol Reprod Biol 2005; 123:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/12\">",
"      Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. Contraception 2005; 71:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/13\">",
"      Meckstroth KR, Whitaker AK, Bertisch S, et al. Misoprostol administered by epithelial routes: Drug absorption and uterine response. Obstet Gynecol 2006; 108:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/14\">",
"      Creinin MD, Carbonell JL, Schwartz JL, et al. A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. Contraception 1999; 59:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/15\">",
"      Sanchez-Ramos L, Danner CJ, Delke I, Kaunitz AM. The effect of tablet moistening on labor induction with intravaginal misoprostol: a randomized trial. Obstet Gynecol 2002; 99:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/16\">",
"      Bhattacharjee N, Saha SP, Ganguly RP, et al. A randomized comparative study on vaginal administration of acetic acid-moistened versus dry misoprostol for mid-trimester pregnancy termination. Arch Gynecol Obstet 2012; 285:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/17\">",
"      Pongsatha S, Tongsong T. Randomized controlled study comparing misoprostol moistened with normal saline and with acetic acid for second-trimester pregnancy termination. Is it different? J Obstet Gynaecol Res 2011; 37:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/18\">",
"      Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med 2001; 344:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/19\">",
"      Goyal V. Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: a systematic review. Obstet Gynecol 2009; 113:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/20\">",
"      Kim JO, Han JY, Choi JS, et al. Oral misoprostol and uterine rupture in the first trimester of pregnancy: a case report. Reprod Toxicol 2005; 20:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/21\">",
"      Daskalakis GJ, Mesogitis SA, Papantoniou NE, et al. Misoprostol for second trimester pregnancy termination in women with prior caesarean section. BJOG 2005; 112:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/22\">",
"      Dickinson JE. Misoprostol for second-trimester pregnancy termination in women with a prior cesarean delivery. Obstet Gynecol 2005; 105:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/23\">",
"      El-Matary A, Navaratnarajah R, Economides DL. Ultrasound diagnosis of uterine dehiscence following mifepristone/misoprostol regime in early second trimester termination. J Obstet Gynaecol 2006; 26:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/24\">",
"      Mazouni C, Provensal M, Porcu G, et al. Termination of pregnancy in patients with previous cesarean section. Contraception 2006; 73:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/25\">",
"      Nayki U, Taner CE, Mizrak T, et al. Uterine rupture during second trimester abortion with misoprostol. Fetal Diagn Ther 2005; 20:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/26\">",
"      Mazzone ME, Woolever J. Uterine rupture in a patient with an unscarred uterus: a case study. WMJ 2006; 105:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/27\">",
"      Al-Hussaini TK. Uterine rupture in second trimester abortion in a grand multiparous woman. A complication of misoprostol and oxytocin. Eur J Obstet Gynecol Reprod Biol 2001; 96:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/28\">",
"      Syed S, Noreen H, Kahloon LE, Chaudhri R. Uterine rupture associated with the use of intra-vaginal misoprostol during second-trimester pregnancy termination. J Pak Med Assoc 2011; 61:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/29\">",
"      Cuellar Torriente M. Silent uterine rupture with the use of misoprostol for second trimester termination of pregnancy : a case report. Obstet Gynecol Int 2011; 2011:584652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/30\">",
"      Berghella V, Airoldi J, O'Neill AM, et al. Misoprostol for second trimester pregnancy termination in women with prior caesarean: a systematic review. BJOG 2009; 116:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/31\">",
"      Naguib AH, Morsi HM, Borg TF, et al. Vaginal misoprostol for second-trimester pregnancy termination after one previous cesarean delivery. Int J Gynaecol Obstet 2010; 108:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/32\">",
"      Fawzy M, Abdel-Hady el-S. Midtrimester abortion using vaginal misoprostol for women with three or more prior cesarean deliveries. Int J Gynaecol Obstet 2010; 110:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/33\">",
"      Lalitkumar S, Bygdeman M, Gemzell-Danielsson K. Mid-trimester induced abortion: a review. Hum Reprod Update 2007; 13:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/34\">",
"      Ngai SW, Tang OS, Ho PC. Prostaglandins for induction of second-trimester termination and intrauterine death. Best Pract Res Clin Obstet Gynaecol 2003; 17:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/35\">",
"      Vogel D, Burkhardt T, Rentsch K, et al. Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am J Obstet Gynecol 2004; 191:2168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/36\">",
"      Jain JK, Mishell DR Jr. A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion. Am J Obstet Gynecol 1996; 175:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/37\">",
"      Borgatta L, Chen AY, Vragovic O, et al. A randomized clinical trial of the addition of laminaria to misoprostol and hypertonic saline for second-trimester induction abortion. Contraception 2005; 72:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/38\">",
"      Fjerstad M, Trussell J, Lichtenberg ES, et al. Severity of infection following the introduction of new infection control measures for medical abortion. Contraception 2011; 83:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/39\">",
"      Fjerstad M, Trussell J, Sivin I, et al. Rates of serious infection after changes in regimens for medical abortion. N Engl J Med 2009; 361:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/40\">",
"      Meites E, Zane S, Gould C, C. sordellii Investigators. Fatal Clostridium sordellii infections after medical abortions. N Engl J Med 2010; 363:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/41\">",
"      Blanchard K, Shochet T, Coyaji K, et al. Misoprostol alone for early abortion: an evaluation of seven potential regimens. Contraception 2005; 72:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/42\">",
"      Gilbert A, Reid R. A randomised trial of oral versus vaginal administration of misoprostol for the purpose of mid-trimester termination of pregnancy. Aust N Z J Obstet Gynaecol 2001; 41:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/43\">",
"      Bebbington MW, Kent N, Lim K, et al. A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. Am J Obstet Gynecol 2002; 187:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/44\">",
"      Dickinson JE, Evans SF. A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality. Obstet Gynecol 2003; 101:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/45\">",
"      Tang OS, Miao BY, Lee SW, Ho PC. Pilot study on the use of repeated doses of sublingual misoprostol in termination of pregnancy up to 12 weeks gestation: efficacy and acceptability. Hum Reprod 2002; 17:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/46\">",
"      Cheung W, Tang OS, Lee SW, Ho PC. Pilot study on the use of sublingual misoprostol in termination of pregnancy up to 7 weeks gestation. Contraception 2003; 68:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/47\">",
"      Bhattacharjee N, Saha SP, Ghoshroy SC, et al. A randomised comparative study on sublingual versus vaginal administration of misoprostol for termination of pregnancy between 13 to 20 weeks. Aust N Z J Obstet Gynaecol 2008; 48:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/48\">",
"      Ngoc NT, Blum J, Raghavan S, et al. Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception 2011; 83:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/49\">",
"      Ngoc NT, Shochet T, Raghavan S, et al. Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: a randomized controlled trial. Obstet Gynecol 2011; 118:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/50\">",
"      Salakos N, Kountouris A, Botsis D, et al. First-trimester pregnancy termination with 800 microg of vaginal misoprostol every 12 h. Eur J Contracept Reprod Health Care 2005; 10:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/51\">",
"      Carbonell JL, Rodr&iacute;guez J, Velazco A, et al. Oral and vaginal misoprostol 800 microg every 8 h for early abortion. Contraception 2003; 67:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/52\">",
"      Carbonell JL, Velazco A, Varela L, et al. Misoprostol for abortion at 9-12 weeks' gestation in adolescents. Eur J Contracept Reprod Health Care 2001; 6:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/53\">",
"      Carbonell JL, Rodriguez J, Arag&oacute;n S, et al. Vaginal misoprostol 1000 microg for early abortion. Contraception 2001; 63:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/54\">",
"      Velazco A, Varela L, Tanda R, et al. Misoprostol for abortion up to 9 weeks' gestation in adolescents. Eur J Contracept Reprod Health Care 2000; 5:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/55\">",
"      Ngai SW, Tang OS, Chan YM, Ho PC. Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: efficacy and acceptability. Hum Reprod 2000; 15:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/56\">",
"      Tang OS, Wong KS, Tang LC, Ho PC. Pilot study on the use of repeated doses of misoprostol in termination of pregnancy at less than 9 weeks of gestation. Adv Contracept 1999; 15:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/57\">",
"      Esteve JL, Varela L, Velazco A, et al. Early abortion with 800 micrograms of misoprostol by the vaginal route. Contraception 1999; 59:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/58\">",
"      Carbonell Esteve JL, Varela L, Velazco A, et al. Vaginal misoprostol for late first trimester abortion. Contraception 1998; 57:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/59\">",
"      Carbonell JL, Varela L, Velazco A, et al. Vaginal misoprostol for abortion at 10-13 weeks' gestation. Eur J Contracept Reprod Health Care 1999; 4:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/60\">",
"      Carbonell JL, Varela L, Velazco A, Fern&aacute;ndez C. The use of misoprostol for termination of early pregnancy. Contraception 1997; 55:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/61\">",
"      Caliskan E, Dilbaz S, Doger E, et al. Randomized comparison of 3 misoprostol protocols for abortion induction at 13-20 weeks of gestation. J Reprod Med 2005; 50:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/62\">",
"      von Hertzen H, Piaggio G, Huong NT, et al. Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. Lancet 2007; 369:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/63\">",
"      Tang OS, Lau WN, Chan CC, Ho PC. A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG 2004; 111:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/64\">",
"      von Hertzen H, Piaggio G, Wojdyla D, et al. Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled equivalence trial. Hum Reprod 2009; 24:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/65\">",
"      Ganguly RP, Saha SP, Mukhopadhyay S, et al. A comparative study on sublingual versus oral and vaginal administration of misoprostol for late first and early second trimester abortion. J Indian Med Assoc 2010; 108:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/66\">",
"      Cabrera Y, Fern&aacute;ndez-Guisasola J, Lobo P, et al. Comparison of sublingual versus vaginal misoprostol for second-trimester pregnancy termination: a meta-analysis. Aust N Z J Obstet Gynaecol 2011; 51:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/67\">",
"      Wildschut H, Both MI, Medema S, et al. Medical methods for mid-trimester termination of pregnancy. Cochrane Database Syst Rev 2011; :CD005216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/68\">",
"      Blum J, Raghavan S, Dabash R, et al. Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. Int J Gynaecol Obstet 2012; 118:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/69\">",
"      Sayette H, Redwine D, Sivin I, et al.. Buccal use of misoprostol alone for early abortion: The experience in four Latin American countries (abstract). Contraception 2011; 84:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/70\">",
"      Winikoff B, Dzuba IG, Creinin MD, et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstet Gynecol 2008; 112:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/71\">",
"      Middleton T, Schaff E, Fielding SL, et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception 2005; 72:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/72\">",
"      Kapp N, Borgatta L, Stubblefield P, et al. Mifepristone in second-trimester medical abortion: a randomized controlled trial. Obstet Gynecol 2007; 110:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/73\">",
"      Patel A, Talmont E, Morfesis J, et al. Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy. Contraception 2006; 73:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/74\">",
"      Ellis SC, Kapp N, Vragpvoc O, Borgata L. Randomized trial of buccal versus vaginal misoprostol for induction of second trimester abortion. Contraception 2010; 81:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/75\">",
"      Liaquat NF, Javed I, Shuja S, et al. Therapeutic termination of second trimester pregnancies with low dose misoprostol. J Coll Physicians Surg Pak 2006; 16:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/76\">",
"      Makhlouf AM, Al-Hussaini TK, Habib DM, Makarem MH. Second-trimester pregnancy termination: comparison of three different methods. J Obstet Gynaecol 2003; 23:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/77\">",
"      Feldman DM, Borgida AF, Rodis JF, et al. A randomized comparison of two regimens of misoprostol for second-trimester pregnancy termination. Am J Obstet Gynecol 2003; 189:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/78\">",
"      Fa&uacute;ndes A, Fiala C, Tang OS, Velasco A. Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy. Int J Gynaecol Obstet 2007; 99 Suppl 2:S172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/79\">",
"      Guix C, Palacio M, Figueras F, et al. Efficacy of two regimens of misoprostol for early second-trimester pregnancy termination. Fetal Diagn Ther 2005; 20:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/80\">",
"      Bugalho A, Fa&uacute;ndes A, Jamisse L, et al. Evaluation of the effectiveness of vaginal misoprostol to induce first trimester abortion. Contraception 1996; 53:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/81\">",
"      Wong KS, Ngai CS, Yeo EL, et al. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial. Hum Reprod 2000; 15:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/82\">",
"      Herabutya Y, Chanrachakul B, Punyavachira P. A randomised controlled trial of 6 and 12 hourly administration of vaginal misoprostol for second trimester pregnancy termination. BJOG 2005; 112:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/83\">",
"      Dickinson JE, Evans SF. The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination. Am J Obstet Gynecol 2002; 186:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/84\">",
"      Edwards RK, Sims SM. Outcomes of second-trimester pregnancy terminations with misoprostol: comparing 2 regimens. Am J Obstet Gynecol 2005; 193:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/85\">",
"      Dodd J, O'Brien L, Coffey J. Misoprostol for second and third trimester termination of pregnancy: a review of practice at the Women's and Children's Hospital, Adelaide, Australia. Aust N Z J Obstet Gynaecol 2005; 45:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/86\">",
"      Langer BR, Peter C, Firtion C, et al. Second and third medical termination of pregnancy with misoprostol without mifepristone. Fetal Diagn Ther 2004; 19:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/87\">",
"      Prachasilpchai N, Russameecharoen K, Borriboonhirunsarn D. Success rate of second-trimester termination of pregnancy using misoprostol. J Med Assoc Thai 2006; 89:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/88\">",
"      Ho PC, Blumenthal PD, Gemzell-Danielsson K, et al. Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. Int J Gynaecol Obstet 2007; 99 Suppl 2:S178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/89\">",
"      Jain JK, Dutton C, Harwood B, et al. A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Hum Reprod 2002; 17:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/90\">",
"      Borgatta L, Kapp N, Society of Family Planning. Clinical guidelines. Labor induction abortion in the second trimester. Contraception 2011; 84:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/91\">",
"      Shaw D. Misoprostol for reproductive health: Dosage recommendations. Int J Gynaecol Obstet 2007; 99 Suppl 2:S155.",
"     </a>",
"    </li>",
"    <li>",
"     Safe abortion: Technical and policy guidelines for health systems. World Health Organization, Geneva, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/93\">",
"      Green J, Borgatta L, Sia M, et al. Intervention rates for placental removal following induction abortion with misoprostol. Contraception 2007; 76:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/94\">",
"      Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol 2003; 109:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/95\">",
"      Harwood B, Meckstroth KR, Mishell DR, Jain JK. Serum beta-human chorionic gonadotropin levels and endometrial thickness after medical abortion. Contraception 2001; 63:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/96\">",
"      Luise C, Jermy K, Collons WP, Bourne TH. Expectant management of incomplete, spontaneous first-trimester miscarriage: outcome according to initial ultrasound criteria and value of follow-up visits. Ultrasound Obstet Gynecol 2002; 19:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/97\">",
"      Creinin MD, Harwood B, Guido RS, et al. Endometrial thickness after misoprostol use for early pregnancy failure. Int J Gynaecol Obstet 2004; 86:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/98\">",
"      Reynolds A, Ayres-de-Campos D, Costa MA, Montenegro N. How should success be defined when attempting medical resolution of first-trimester missed abortion? Eur J Obstet Gynecol Reprod Biol 2005; 118:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/99\">",
"      Reeves MF, Fox MC, Lohr PA, Creinin MD. Endometrial thickness following medical abortion is not predictive of subsequent surgical intervention. Ultrasound Obstet Gynecol 2009; 34:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/100\">",
"      Honkanen H, Piaggio G, Hertzen H, et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. BJOG 2004; 111:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/101\">",
"      Ngai SW, Tang OS, Ho PC. Randomized comparison of vaginal (200 microg every 3 h) and oral (400 microg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy. Hum Reprod 2000; 15:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/102\">",
"      Baird DT. Medical abortion in the first trimester. Best Pract Res Clin Obstet Gynaecol 2002; 16:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/103\">",
"      Jain JK, Meckstroth KR, Park M, Mishell DR Jr. A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination. Contraception 1999; 60:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/104\">",
"      Chong YS, Chua S, Arulkumaran S. Severe hyperthermia following oral misoprostol in the immediate postpartum period. Obstet Gynecol 1997; 90:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/105\">",
"      Philip NM, Winikoff B, Moore K, Blumenthal P. A consensus regimen for early abortion with misoprostol. Int J Gynaecol Obstet 2004; 87:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/106\">",
"      Shannon C, Brothers LP, Philip NM, Winikoff B. Infection after medical abortion: a review of the literature. Contraception 2004; 70:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/107\">",
"      Fischer M, Bhatnagar J, Guarner J, et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N Engl J Med 2005; 353:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/108\">",
"      Sinave C, Le Templier G, Blouin D, et al. Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease. Clin Infect Dis 2002; 35:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/109\">",
"      Couzin J. infectious disease. RU-486-linked deaths open debate about risky bacteria. Science 2006; 312:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/110\">",
"      Winikoff B. Clostridium sordellii infection in medical abortion. Clin Infect Dis 2006; 43:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/111\">",
"      Aronoff DM, Hao Y, Chung J, et al. Misoprostol impairs female reproductive tract innate immunity against Clostridium sordellii. J Immunol 2008; 180:8222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/112\">",
"      Jain JK, Harwood B, Meckstroth KR, Mishell DR. Early pregnancy termination with vaginal misoprostol combined with loperamide and acetaminophen prophylaxis. Contraception 2001; 63:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/113\">",
"      Daskalakis G, Papantoniou N, Mesogitis S, et al. Sonographic findings and surgical management of a uterine rupture associated with the use of misoprostol during second-trimester abortion. J Ultrasound Med 2005; 24:1565.",
"     </a>",
"    </li>",
"    <li>",
"     Misoprostol and teratology: Reviewing the evidence, Philip, N, Shannon, C, Winikoff, B (Eds), Population Council, New York 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/115\">",
"      Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG 2000; 107:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/116\">",
"      Castilla EE, Orioli IM. Teratogenicity of misoprostol: data from the Latin-American Collaborative Study of Congenital Malformations (ECLAMC). Am J Med Genet 1994; 51:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/117\">",
"      Addar MH. Methotrexate embryopathy in a surviving intrauterine fetus after presumed diagnosis of ectopic pregnancy: case report. J Obstet Gynaecol Can 2004; 26:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/118\">",
"      Csapo AI. The prospects of PGs in postconceptional therapy. Prostaglandins 1973; 3:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/42/28330/abstract/119\">",
"      Dodd JM, Crowther CA. Misoprostol versus cervagem for the induction of labour to terminate pregnancy in the second and third trimester: a systematic review. Eur J Obstet Gynecol Reprod Biol 2006; 125:3.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5434 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_42_28330=[""].join("\n");
var outline_f27_42_28330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Absolute contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Relative contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk factors for uterine rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PRETREATMENT EVALUATION AND PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DATA ON DRUG ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Route of administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dose and dosing interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Number of doses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      9 or less weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      10 to 12 weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      13 to 22 weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      23 or more weeks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MONITORING DURING TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      At-home treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      In-clinic treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Gastrointestinal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Prevention of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Incomplete abortion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - First trimester",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Second trimester",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Uterine rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      MISOPROSTOL-ALONE COMPARED TO OTHER REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Misoprostol versus other prostaglandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Misoprostol versus mifepristone/misoprostol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Misoprostol versus methotrexate/misoprostol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Pretreatment considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Clinical protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Posttreatment issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5434\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5434|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/17/3357\" title=\"table 1\">",
"      Misoprost abortion rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/22/35181\" title=\"table 2\">",
"      Misoprostol-only protocol",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=related_link\">",
"      Choosing the route of delivery after cesarean birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=related_link\">",
"      Incidence, etiology, and prevention of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=related_link\">",
"      Mifepristone for the medical termination of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=related_link\">",
"      Overview of pregnancy termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/47/42739?source=related_link\">",
"      Patient information: Abortion (pregnancy termination) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2841?source=related_link\">",
"      Spontaneous abortion: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4453?source=related_link\">",
"      Surgical termination of pregnancy: First trimester",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41993?source=related_link\">",
"      Techniques for ripening the unfavorable cervix prior to induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=related_link\">",
"      Termination of pregnancy: Second trimester",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_42_28331="Indications for liver biopsy";
var content_f27_42_28331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for liver biopsy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Diagnosis, grading, and staging of alcoholic liver disease, nonalcoholic steatohepatitis, and autoimmune hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grading and staging of chronic hepatitis B and C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Diagnosis of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Hemochromatosis (quantitative estimation of hepatic iron)",
"         </li>",
"         <li>",
"          Wilson's disease (quantitative hepatic copper)",
"         </li>",
"         <li>",
"          Focal liver lesions",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Evaluation of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Cholestatic liver disease: primary biliary cirrhosis, primary sclerosing cholangitis",
"         </li>",
"         <li>",
"          Abnormal liver biochemical tests in a patient with a negative or inconclusive serologic work-up",
"         </li>",
"         <li>",
"          Treatment efficacy",
"         </li>",
"         <li>",
"          Side effects of treatment regimens (such as methotrexate for rheumatoid arthritis)",
"         </li>",
"         <li>",
"          Post liver transplant by protocol or for evaluation of abnormal liver biochemical tests",
"         </li>",
"         <li>",
"          Donor liver",
"         </li>",
"         <li>",
"          Fever of unknown origin",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_42_28331=[""].join("\n");
var outline_f27_42_28331=null;
var title_f27_42_28332="Features of hemorrhage I";
var content_f27_42_28332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of major causes of immune or idiopathic alveolar hemorrhage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Extrapulmonary features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Essential diagnostic criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        ABMA disease",
"       </td>",
"       <td>",
"        GN &gt;90%",
"       </td>",
"       <td rowspan=\"2\">",
"        +ABMA",
"       </td>",
"       <td>",
"        +Serum ABMA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extrarenal disease rare",
"       </td>",
"       <td>",
"        Linear IgG in glomeruli",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        SLE",
"       </td>",
"       <td>",
"        GN &gt;90%",
"       </td>",
"       <td rowspan=\"2\">",
"        +ANA",
"       </td>",
"       <td rowspan=\"2\">",
"        Clinical features, +ANA, immune complexes in glomeruli by IF, EM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extrarenal disease common (arthritis, serositis, purpura, photosensitivity)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        WG",
"       </td>",
"       <td class=\"sublist1_start\">",
"        GN &gt;90% extrarenal disease",
"       </td>",
"       <td rowspan=\"3\">",
"        +ANCA",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Necrotizing granulomatous vasculitis in upper airway or lung biopsy",
"        </p>",
"        <p>",
"         or",
"        </p>",
"        <p>",
"         Pauci-immune necrotizing GN with extensive upper airway disease or cavitary lung nodules",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Distinctive: upper airway disease, pulmonary nodules&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nonspecific (arthritis, purpura, mononeuropathy)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Nonspecific systemic necrotizing vasculitis (microscopic polyarteritis, polyangiitis, overlap syndrome)",
"       </td>",
"       <td>",
"        GN &gt;90% extrarenal disease variably present (arthritis, purpura, mononeuropathy)",
"       </td>",
"       <td>",
"        &plusmn;ANCA (usually + if include p-ANCA)",
"       </td>",
"       <td>",
"        Necrotizing, crescentic GN (or pathologic evidence of vasculitis elsewhere) and exclude WG to extent possible",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Idiopathic pulmonary hemosiderosis",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Exclusion of all other causes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ABMA: antibasement membrane antibody; GN: glomerulonephritis; SLE: systemic lupus erythematosus; ANA: antinuclear antibody; IF: immunofluorescence; EM: electron microscopy; WG: granulomatosis with polyangiitis (Wegener's); ANCA: antineutrophil cytoplasmic antibody; p-ANCA: perinuclear ANCA; %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Leatherman JL. In: Immunologically Mediated Pulmonary Diseases, Lynch JP, DeRemee RA (Eds), JB Lippincott, Philadelphia, 1991, p.490.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_42_28332=[""].join("\n");
var outline_f27_42_28332=null;
var title_f27_42_28333="Contents: Emergency medical services/Disaster medicine";
var content_f27_42_28333=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?10/42/10926\">",
"       Adult and Pediatric Emergency Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Emergency medical services/Disaster medicine",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Emergency medical services/Disaster medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/20/8521\">",
"           Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/46/22247\">",
"           Identifying and managing casualties of biological terrorism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/1/10264\">",
"           Performance of prehospital fibrinolysis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-37F85A1B74-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f27_42_28333=[""].join("\n");
var outline_f27_42_28333=null;
var title_f27_42_28334="Contents: Electrocardiography";
var content_f27_42_28334=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/3/5182\">",
"       Cardiovascular Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Electrocardiography",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Electrocardiography",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Arrhythmias",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/19/31034\">",
"           Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/35/39481\">",
"           Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/5/4184\">",
"           Electrocardiographic abnormalities and conduction disturbances in athletes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/53/15192\">",
"           Electrocardiographic and electrophysiologic features of type I atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12165\">",
"           Electrocardiographic and electrophysiologic features of type II atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/62/12266\">",
"           Mechanisms of atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/48/5898\">",
"           T wave (repolarization) alternans: Clinical aspects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/36/9800\">",
"           T wave (repolarization) alternans: Technical aspects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/42/26278\">",
"           The electrocardiogram in atrial fibrillation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Conduction disturbances",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/56/18308\">",
"           Basic approach to delayed intraventricular conduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/11/4282\">",
"           Conduction abnormalities after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/8/10376\">",
"           Congenital third degree (complete) atrioventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/62/12261\">",
"           Course and treatment of chronic bifascicular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/38/38505\">",
"           Early repolarization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/5/4184\">",
"           Electrocardiographic abnormalities and conduction disturbances in athletes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/13/9431\">",
"           Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/38/41574\">",
"           First degree atrioventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/31/16886\">",
"           Left anterior fascicular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/54/39784\">",
"           Left bundle branch block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/49/40723\">",
"           Left median (middle or septal) fascicular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/2/16420\">",
"           Left posterior fascicular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/6/10344\">",
"           Right bundle branch block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/42/18087\">",
"           Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/62/998\">",
"           Second degree atrioventricular block: Mobitz type II",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/59/15285\">",
"           Third degree (complete) atrioventricular block",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General electrocardiography",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/40/5763\">",
"           Advanced ECG test",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/44/9923\">",
"           Basic ECG test",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/16/262\">",
"           Basic principles of electrocardiographic interpretation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/10/22689\">",
"           Differential diagnosis of basic electrocardiographic abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/7/23669\">",
"           Electrocardiogram in pericarditis and pericardial effusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/13/3285\">",
"           Electrocardiographic diagnosis of left ventricular hypertrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/48/6916\">",
"           Intermediate ECG test",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/33/38422\">",
"           Myocardial action potential and action of antiarrhythmic drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/0/36868\">",
"           Pathogenesis and diagnosis of Q waves on the electrocardiogram",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/48/5898\">",
"           T wave (repolarization) alternans: Clinical aspects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/36/9800\">",
"           T wave (repolarization) alternans: Technical aspects",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Myocardial ischemia and infarction",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/24/11658\">",
"           Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/26/4521\">",
"           Electrocardiogram in the prognosis of myocardial infarction or unstable angina",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/13/9431\">",
"           Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/0/36868\">",
"           Pathogenesis and diagnosis of Q waves on the electrocardiogram",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-D54B7CDD67-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f27_42_28334=[""].join("\n");
var outline_f27_42_28334=null;
var title_f27_42_28335="Monteggia fracture in a child";
var content_f27_42_28335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Monteggia fracture in a child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral (Panel A) and anteroposterior (Panel B) plain radiographs showing proximal ulnar fracture with dislocation of the radial head (indicated by lack of alignment of the radial head with the capitellum).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_42_28335=[""].join("\n");
var outline_f27_42_28335=null;
